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ABSTRACT 
NCL disorders, neuronal ceroid lipofuscinoses, comprise the most common group of 
neurodegenerative diseases in children. The incidence of these hereditary disorders 
is approximately 1 : 12 500 worldwide. Features common to all NCLs include 
accumulation of the autofluorescent intracellular storage material, ceroid 
lipofuscine, in the tissues of patients, and progressive neuronal death, leading to 
blindness, psychomotor retardation, and premature death. Disease-causing mutations 
have been characterized in eight different genes so far, but the cellular mechanisms 
leading to neurodegeneration are still largely unknown. 
Infantile NCL (INCL), together with congenital NCL, is the most severe form of the 
NCL disorders. The clinical manifestations include progressive visual failure, 
epileptic seizures, and ataxia. INCL patients die approximately at the age of ten. The 
CLN1 gene encoding for the PPT1 (palmitoyl protein thioesterase 1) enzyme is 
mutated in INCL. PPT1 removes a palmitate moiety from proteins in experimental 
conditions, but its substrates in vivo are not known. CLN5 is a Finnish variant of late 
infantile NCL (vLINCLFin). The defective gene, CLN5, encoding for the CLN5 
protein, was found in 1998. The first symptoms of vLINCLFin, visual failure and 
motor deterioration, are observed before school age. Progressive mental retardation 
leads to death at early adulthood. The function of CLN5 has remained unknown. 
The aim of this thesis was to elucidate the disease mechanisms of these two NCL 
diseases enriched in Finland. The focus has been on the molecular interactions of the 
defective proteins. It was previously known that the intracellular localization of 
PPT1 is different in neurons than in other cell types. In neurons, it localizes mainly 
to axonal presynaptic compartments instead of lysosomes, where it is found in other 
cell types. In this study we observed that the processing of PPT1 was different 
between neuronal cells and connective tissue cells, fibroblasts. Furthermore, the 
intracellular trafficking of overexpressed PPT1 was found to differ from the classic 
trafficking pathway utilized by another lysosomal enzyme, AGA. These findings 
implicate novel properties for the PPT1 enzyme in neurons, and are significant when 
designing therapeutic strategies for INCL. PPT1 was also found in high molecular 
weight complexes and its activity was separated into two fractions. The protein that 
  
formed a complex with PPT1 and purified with it was identified as the -subunit of 
the mitochondrial ATP synthase. Later we found that PPT1 interacted with the entire 
F1-complex that includes the -subunit. The F1-complex has been localized to the 
cell surface in addition to mitochondria, and in hepatocytes it has been shown to 
participate in HDL metabolism. The connection between PPT1 and the localization 
of F1-subunits was studied utilizing the INCL-disease model, the genetically 
modified Ppt1-deficient mice. Our results show that in Ppt1-deficient neurons, the 
amount of F1-subunits was specifically increased on the cell surface, while this was 
not detected in fibroblasts. Studies conducted with neuronal cells and serum samples 
further showed several changes in lipid metabolism both at the cellular and systemic 
levels, since the cellular uptake of apolipoproteins and the lipoprotein particle size 
were altered in Ppt1-deficient mice compared to controls. Thus, the identification of 
the first interaction partner for PPT1 led on to the studies connecting the altered 
neuronal function and disturbancies in lipid metabolism in INCL. 
In the last part of the thesis, the focus was to elucidate the interactions between 
different NCL proteins. The reasoning behind this was the possible common 
metabolic route affected in NCL disorders, leading to similar clinical and 
neuropathological manifestations. CLN5 was chosen as the center molecule, as it 
was already known to interact with two other NCL proteins, CLN2 and CLN3, and it 
represents an NCL protein with an entirely elusive function. We detected three novel 
interactions between CLN5 and other NCL proteins, including an interaction with 
PPT1. The interaction between CLN5 and PPT1 turned out to be especially strong, 
as both proteins affected the intracellular transport of each other. In addition, we 
detected an interaction between CLN5 and the F1-complex, further supporting a 
functional connection between CLN5 and PPT1. The multiple interactions between 
CLN5 and other NCL proteins suggest a connection between the NCL subtypes at 
the cellular level, where they possibly modify the phenotypes of each other. This is 
supported by the bidirectional interconnection of CLN5 and PPT1 in intracellular 
protein sorting. 
The main results of this thesis elicit information about the neuronal function of 
PPT1. The connection between INCL and neuronal lipid metabolism is strengthened 
by the characterization of the first interaction partner for PPT1, introducing a new 
perspective to this rather poorly characterized subject. The evidence of the 
interactions between NCL proteins provides the basis for future research trying to 
untangle the NCL disease mechanisms and the development of therapies for these 
diseases. 
Keywords: neurodegeneration, developmental disturbance, neuronal ceroid 
lipofuscinosis, interaction partner, lipid metabolism, metabolic route. 
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TIIVISTELMÄ 
Neuronaaliset seroidilipofuskinoosit eli NCL-taudit ovat yleisin lasten hermostoa 
rappeuttavien sairauksien ryhmä. Näiden perinnöllisten tautien esiintymistiheys on 
maailmanlaajuisesti noin 1 : 12 500. Kaikille NCL-taudeille yhteinen piirre on 
solunsisäinen autofluoresoiva kertymämateriaali, ”seroidi lipofuskiini”, sekä etenevä 
hermosolujen tuhoutuminen, joka johtaa sokeutumiseen, psykomotorisen kehityksen 
häiriintymiseen ja ennenaikaiseen kuolemaan. NCL-tauteja aiheuttavia mutaatiota 
on tähän mennessä löydetty kahdeksasta eri geenistä, mutta hermosolukuolemaan 
johtavat solutason tapahtumat ovat suurelta osin tuntemattomia. 
Infantiili NCL (INCL) on synnynnäisen NCL:n ohella NCL-taudeista vakavin. 
Taudin kliiniseen kuvaan kuuluu mm. sokeutuminen, epilepsia ja ataksia. INCL-
potilaat kuolevat noin kymmenvuotiaina. INCL-taudissa palmityyliproteiini-
tioesteraasia eli PPT1:tä koodittava CLN1-geeni on mutatoitunut. PPT1:n on todettu 
poistavan palmitaatti-rasvahappotähdettä proteiineista koeolosuhteissa, mutta sen 
toiminta elimistössä on vielä tuntematon. CLN5 on suomalainen muunnos 
myöhäisestä lapsuusiän NCL-taudista (vLINCLFin). Taudissa vioittunutta CLN5-
proteiinia koodittava CLN5-geeni löydettiin vuonna 1998. Taudin ensimmäiset 
oireet, näön heikkeneminen ja motorisen kehityksen taantuminen, havaitaan 
kouluikään mennessä. Etenevä kehitysvammaisuus johtaa potilaan kuolemaan 
varhaisessa aikuisiässä. CLN5-proteiinin toimintaa ei toistaiseksi tunneta. 
Tässä väitöskirjatyössä pyrittiin selvittämään näiden kahden Suomessa rikastuneen 
NCL-taudin tautimekanismeja keskittymällä taudeissa vioittuneiden proteiinien 
molekyylitason vuorovaikutusten selvittämiseen. Aiemmin oli tiedossa, että PPT1:n 
solutason paikantuminen on erilaista hermosoluissa verrattuna muihin 
solutyyppeihin. Hermosoluissa PPT1 rikastuu niiden viejähaarakkeisiin, aksoneihin, 
lysosomien sijaan. Väitöskirjatyössä havaittiin, että PPT1:n prosessointi on erilaista 
hermosolujen ja sidekudossolujen välillä. PPT1:n solunsisäisen kuljetuksen 
havaittiin eroavan toisen, klassista kuljetusreittiä käyttävän lysosomaalisen AGA-
entsyymin kuljetuksesta. Löydöksemme osoittavat, että PPT1:llä on hermosoluille 
erityisiä ominaisuuksia, jotka voivat olla merkityksellisiä INCL:n hoitomuotoja 
kehitettäessä. PPT1:n todettiin muodostavan suurikokoisia komplekseja, ja olevan 
  
aktiivinen kahdessa eri muodossa. PPT1:n kanssa kompleksin muodostava proteiini 
tunnistettiin mitokondriaaliseksi ATP-syntaasin -alayksiköksi. Tutkimuksissamme 
selvisi, että PPT1 on vuorovaikutuksessa ATP-syntaasin F1-kompleksin kanssa, 
jonka osa -alayksikkö on. F1-kompleksin tiedetään paikantuvan mitokondrioiden 
lisäksi solun pinnalle, ja osallistuvan maksasoluissa HDL-rasva-aineenvaihduntaan. 
F1-alayksiköiden solutason paikantumista tutkittiin INCL-tautimallin, Ppt1-
siirtogeenisten hiiren hermosoluissa ja sidekudossoluissa. Havaitsimme, että F1-
alayksiköiden määrä on lisääntynyt hermosolun pinnalla INCL-soluissa, kun taas 
sidekudossoluissa muutosta ei havaittu. Jatkotutkimukset hermoston soluilla ja 
veriseeruminäytteillä osoittivat rasva-aineenvaihdunnan muutoksia sekä solutasolla 
että systeemisesti, sillä apolipoproteiinien soluunkuljetuksessa ja lipoproteiini-
partikkeleiden koossa havaittiin merkittäviä eroja Ppt1-siirtogeenisten ja 
kontrollihiirten välillä. PPT1:n ensimmäisen vuorovaikutuskumppanin 
tunnistaminen pohjusti täten uudenlaisen yhteyden löytymistä hermosolujen 
muuttuneen toiminnan ja rasva-aineenvaihdunnan välillä INCL-taudissa.  
Väitöskirjan viimeisessä osatyössä keskityttiin NCL-proteiinien välisten 
vuorovaikutusten selvittämiseen, sillä NCL-tautien yhtenäisen kliinisen kuvan 
takana ollaan arveltu olevan NCL-proteiinien toimiminen saman 
aineenvaihduntareitin varrella. CLN5-proteiini valittiin keskusproteiiniksi, sillä sen 
tiedettiin vuorovaikuttavan jo kahden muun NCL-proteiinin, CLN2:n ja CLN3:n  
kanssa. Havaitsimme näiden lisäksi kolme uutta NCL-proteiinien välistä 
sitoutumista. CLN5:n ja PPT1:n välinen vuorovaikutus osoittautui erityisen 
voimakkaaksi, sillä se vaikutti proteiinien paikantumiseen solussa. Lisäksi 
havaitsimme, että myös CLN5 sitoutuu F1-kompleksiin, edelleen vahvistaen 
mahdollista toiminnallista yhteyttä PPT1:n ja CLN5:n välillä. CLN5:n 
vuorovaikutukset lukuisten muiden NCL-proteiinien kanssa viittaavat solutason 
yhteyden olemassaoloon eri NCL-tautien välillä, vaikuttaen mahdollisesti tautien 
ilmiasuun. Tätä tukee löydös, jossa osoitettiin molemminpuolinen vaikutus CLN5- 
ja PPT1-proteiineille toistensa solunsisäisessä kuljetuksessa. 
Väitöskirjan tulokset tuovat lisätietoa PPT1:n toiminnasta hermosolussa. PPT1:n 
ensimmäisen vuorovaikutuskumppanin kuvaus vahvistaa INCL-taudin ja PPT1:n 
yhteyttä hermosolun rasva-aineenvaihduntaan tuoden mielenkiintoisen näkökulman 
aiheeseen, josta toistaiseksi tiedetään varsin vähän. Lisäksi todisteet NCL-
proteiinien välisistä vuorovaikutuksista solutasolla vahvistuivat, antaen pohjaa 
tuleville tutkimuksille NCL-tautimekanismien selvittämiseksi ja hoitomuotojen 
kehittämiseksi. 
Asiasanat: hermosolukuolema, kehityshäiriö, neuronaalinen seroidilipofuskinoosi, 
vuorovaikutuskumppani, rasva-aineenvaihdunta, aineenvaihduntareitti.  
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ABBREVIATIONS 
2BP  2-bromopalmitate 
aa  amino acid(s) 
ANCL  adult neuronal ceroid lipofuscinosis (CLN4) 
apoA-I  apolipoprotein A-I 
apoE  apolipoprotein E 
ATP  adenosine triphosphate 
BMP  bis(monoacylglycero)phosphate 
bp  base pair 
cDNA  complementary DNA 
CHO cells  Chinese hamster ovary cells 
CLN ceroid lipofuscinosis, neuronal (in gene and 
protein nomenclature) 
CLN5/Cln5  human/mouse CLN5 gene 
CLN5/Cln5  human/mouse CLN5 protein 
CNS  central nervous system 
COS-1 cells  African green monkey kidney cells 
DNA  deoxyribonucleic acid 
ECL  enhanced chemiluminescence 
ER  endoplasmic reticulum 
GTP  guanosine triphosphate 
HDL  high-density lipoprotein 
HeLa cells  human cervical tumour cells 
INCL  infantile neuronal ceroid lipofuscinosis (CLN1) 
JNCL  juvenile neuronal ceroid lipofuscinosis (CLN3) 
kb  kilobase(s) 
 11 
kDa  kilodalton(s) 
LBPA  lysobisphosphatic acid 
MPR  mannose 6-phosphate receptor 
mRNA  messenger RNA 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PC12 cells  rat adrenal medulla pheochromocytoma cells 
PCR  polymerase chain reaction 
PPT1/Ppt1 human/mouse palmitoyl protein thioesterase 1 
protein (CLN1) 
PTM  post-translational modification 
RNA  ribonucleic acid 
RT  room temperature 
SDS  sodium dodecyl sulphate 
SFV  Semliki Forest virus 
TIRF  total internal reflection fluorescence 
UTR  untranslated region 
vLINCL variant form of late infantile neuronal ceroid 
lipofuscinosis (CLN2) 
vLINCLFin Finnish variant form of late infantile neuronal 
ceroid lipofuscinosis (CLN5) 
wt  wild type 
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1 INTRODUCTION 
Disorders resulting from degenerative changes in the nervous system are progressive 
and incurable. They become more common as the population ages and influence the 
lives of millions of people worldwide. Cellular events leading to neurodegeneration 
are still mostly unknown. Environmental and inherited factors affect neuron 
survival, and neurodegenerative diseases are often the sum of both factors. 
Monogenic diseases, besides being important study subjects in their own right, offer 
a model for studying the mechanisms of neurodegeneration. Neuronal ceroid 
lipofuscinoses, or NCLs, are a group of monogenic, autosomal recessively inherited 
diseases affecting mostly children. NCLs cause severe neurodegeneration, resulting 
in the deterioration of motor and mental skills and leading to premature death 
(Haltia 2003). NCLs resemble each other histopathologically; the accumulation of 
storage material in most cell types, especially in neurons, is associated with massive 
and selective neuronal loss. In Finland, four forms of NCL are more common than 
elsewhere, namely infantile (INCL), Finnish variant late infantile (vLINCLFin), 
juvenile (JNCL), and Northern epilepsy. Here, the focus will be on INCL (CLN1) 
and vLINCLFin (CLN5). 
The incidence of INCL in Finland is 1:20000, meaning that approximately three 
affected children are born each year. The first symptoms appear around the age of 
one, when a child starts to lose already learnt cognitive and motor skills. As the 
disease progresses, irritability, visual failure, progressive decline in psychomotor 
skills, and epileptic seizures appear. By the age of three, the patients have lost active 
movements and social and visual contact with their environment, and they die 
around the age of ten (Santavuori et al. 2000). vLINCLFin is a rare form of NCL, but 
in Southern Ostrobothnia its local incidence is 1:1500 (Jarvela 1991). Altogether, 
about 30 CLN5 cases have been reported. Slight clumsiness and learning problems 
are the first symptoms of CLN5 and they appear before school age. Ataxia, 
myoclonia, and epilepsy start before the age of 10 and the patients become 
wheelchair-bound at 9-13 years of age (Santavuori et al. 2000). 
INCL is caused by mutations in the CLN1 gene that disrupt the structure of the 
encoded protein, palmitoyl protein thioesterase 1 (PPT1) (Vesa et al. 1995). PPT1 is 
a soluble enzyme cleaving a palmitate moiety from proteins. Its in vivo substrates 
are still unknown, as is the reason for neuron-specific cell loss. Finnish variant 
LINCL patients carry mutations in the CLN5 gene, preventing the yet unknown 
function of the corresponding CLN5 protein (Savukoski et al. 1998). In this thesis, 
the aim was to explore the interaction partners for PPT1 and CLN5 in order to gain 
insight into their normal functions and to the mechanisms behind the neuronal death 
in this group of diseases. 
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2 REVIEW OF THE LITERATURE 
2.1 PROTEIN PALMITOYLATION  
2.1.1 Dynamic modification for membrane association 
Proteins are the functional derivatives of the encoding genes. In a protein, the linear 
data stored in a gene is transformed into a three-dimensional, operational unit that 
affects other proteins and genes via interactions with them. It has been estimated that 
the expression of the 20 000 to 25 000 protein-encoding genes in the human genome 
results in more than one million protein products (Nørregaard Jensen 2004). The 
complexity of the human proteome is mainly the consequence of alternative splicing 
and post-translational modifications (PTM). PTMs are covalent processing events on 
amino acids of the polypeptide backbone that change the properties of a protein. 
Over 300 PTMs have been described to occur physiologically, of which the most 
common are glycosylation, phosphorylation, glycosylphosphatidylinositol (GPI) 
anchor formation, proteolytic cleavage, ubiquination, and fatty acid modifications 
such as palmitoylation (Garavelli 2004). 
Palmitate, a 16-carbon saturated fatty acid, is commonly found in plants and 
animals. It is the major fatty acid in palm oil, and thus the name (Fedeli and Jacini 
1971). When attached to proteins, palmitate regulates their functions in diverse 
ways. Palmitoylation facilitates the membrane-association of proteins and regulates 
protein stability. Palmitate is not only a membrane anchor for proteins, as 
transmembrane proteins are also palmitoylated, for instance for lipid raft association 
(Linder and Deschenes 2007). Protein palmitoylation can occur in cysteine residues 
in two ways, N- and S-palmitoylation. The first refers to the addition of palmitate to 
the N-terminal cysteine residue, resulting in a spontaneous conversion of thioester 
linkage to a stable amide linkage present in secreted signalling proteins such as 
Sonic hedgehog (Miura and Treisman 2006). In most cases, palmitate is attached to 
a protein through a reversible, covalent thioester linkage in a process called S-
palmitoylation (Figure 1). Palmitate turnover can be constitutive or regulated, 
depending on the protein (Linder and Deschenes 2007). Protein palmitoylation has 
been a difficult subject to study due to its dynamic nature and lack of a specific 
palmitoylation consensus sequence in the potential palmitoylprotein. Palmitoylation 
has traditionally been studied by in vivo [3H]-palmitate labelling and detection of 
radiolabelled palmitate in the protein of interest. New proteomic methods based on 
acyl-biotinyl exchange chemistry have provided the opportunity for large-scale 
 15 
identification of palmitoylated proteins at the whole-organism level (Drisdel and 
Green 2004, Roth et al. 2006). 
 
 
Figure 1. Protein S-palmitoylation occurs at a cysteine residue in a polypeptide chain 
via a reversible thioester linkage. Protein acyl transferases (PAT) catalyze 
palmitoylation, and acyl protein thioesterases (APT) catalyze the hydrolysis 
of palmitoyl protein. 
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2.1.2 Palmitoylation in the cytoplasm 
S-palmitoylation can occur at the cytoplasmic face of a membrane or in the lumen of 
the secretory pathway (Figure 2). Palmitoylation of cytoplasmic proteins is mostly 
mediated by the recently discovered protein acyltransferases (PATs), 
transmembrane enzymes that were first identified in yeast (Lobo et al. 2002, Roth et 
al. 2002) and later in mammals (Fukata et al. 2004). PATs possess a 50-residue 
cysteine-rich domain with a conserved Asp-His-His-Cys (DHHC) motif needed for 
the PAT acivity. DHHC proteins are located both in endomembranes (e.g. ER and 
Golgi) and the plasma membrane, and function to palmitoylate cytosolic proteins. 
Palmitoylation can occur in tandem with other, stable lipid modifications such as 
prenylation or myristoylation (Smotrys and Linder 2004). Ras proteins and 
heterotrimeric G-proteins (guanyl nucleotide-binding proteins) are small GTPases 
and examples of soluble, dually lipidated proteins. Farnesylation of H- and N-Ras 
provides only a weak membrane-affinity, and palmitoylation increases their 
membrane association (Hancock et al. 1990). Palmitoylation also defines their 
subcellular localization, driving Ras proteins to the plasma membrane (Rocks et al. 
2005). Additionally, the -subunits of G-proteins need palmitoylation for plasma 
membrane targeting and binding with  subunits. Before the G-protein-coupled 
receptor activation, G is bound to  and protected from depalmitoylation. When 
the receptor is activated, G dissociates from  subunits and activates adenylyl 
cyclase. Palmitoylation enhances this activation, and depalmitoylation of G is 
needed for the regulation of downstream effects (Resh 2006). Many transmembrane 
proteins are palmitoylated by the DHHC proteins in the cytoplasmic cysteines near 
the transmembrane domain. For example, many SNARE (soluble N-ethylmaleimide-
sensitive factor attachment protein receptor) proteins, involved in vesicular fusion, 
possess such palmitoylation (Roth et al. 2006).   
2.1.3 Intralumenal palmitoylation 
In the secretory pathway, palmitoylation of secreted signalling proteins is regulated 
by enzymes belonging to a diverse family of membrane-bound O-acyltransferases 
(MBOAT) (Hofmann 2000). Many genes of this family (e.g. Rasp, Skinny 
Hedgehog, and Sightless) have been reported to be involved in the Hedgehog 
signalling pathway through N-palmitoylation (Bijlsma et al. 2004). S-palmitoylation 
has been demonstrated to be important for Wnt-protein signalling (Komekado et al. 
2007, Kurayoshi et al. 2007). Wnt signalling plays a key role during development; 
however, it is also involved in various adult-onset diseases such as cancer, 
osteoporosis, Alzheimer’s disease, and schizophrenia (Caricasole et al. 2005, Patel 
and Karsenty 2002). Wnt binds its receptors Frizzled and a low-density lipoprotein  
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Figure 2. Schematic representation of the intracellular sites of protein palmitoylation. 
1) Palmitoylation of Wnt occurs intralumenally and is catalyzed by proteins 
belonging to the MBOAT-family. Palmitoylation of Ras, catalyzed by the 
DHHC-proteins, occurs at the cytosolic face of the ER or Golgi membrane. 
2) Palmitoylated proteins traffic through the secretory pathway to the 
plasma membrane or become secreted. 3) Depalmitoylated Ras is released 
from the plasma membrane and is able to diffuse to endomembranes to 
become repalmitoylated. Modified from (Hausmann et al. 2007, Linder and 
Deschenes 2007, Resh 2006) 
related protein (LRP) on the cell surface and activates numerous signalling 
pathways, which are usually divided into two main classes, the canonical and 
noncanonical pathways. The canonical pathway results in stabilization of the 
transcription factor -catenin and activation of Wnt target genes (Cadigan 2002). 
The noncanonical pathways include activation of several second messengers such as 
Rho GTPases, calcium, and heterotrimeric G-proteins (Veeman et al. 2003). Wnt 
possesses lipid modifications in two conserved cysteine residues, Cys77 and 
Cys209. The first cysteine is palmitoylated, and the second residue obtains an 
unsaturated lipid moiety, palmitoleic acid (Takada et al. 2006, Willert et al. 2003). 
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Porcupine, a putative acyltransferase, has been suggested to catalyse both acylations 
of Wnt. Palmitoylation on Cys77 is required for Wnt-3a to bind and activate its 
receptors (e.g. LRP6), either by increasing the affinity between the proteins or by 
targeting Wnt to the lipid raft microdomains (Komekado et al. 2007). Palmitoleic 
acid modification is required for the correct intracellular targeting and secretion of 
Wnt (Takada et al. 2006). 
Interestingly, soluble palmitoylproteins that function primarily inside the organelles 
of the secretory pathway rather than become secreted have not been reported so far. 
One explanation for this might be the varying need and probability for membrane 
association. Palmitoylation in the cytosol is important when regulating the capability 
of proteins to diffuse freely or associate with the membrane. Intravesicular proteins 
cannot diffuse long distances and they are constantly relatively close to the 
membrane. Transmembrane proteins also undergo palmitoylation at their cytosolic 
side rather than at their vesicular side. The reason for this could be speculated to be 
associated with redundancy in the regulation of protein palmitoylation; the substrate 
specifities of the DHHC PAT proteins show some overlap at least in yeast (Roth et 
al. 2006). Further, the depalmitoylation of transmembrane proteins from the 
cytosolic side would not be dependent on the location of the palmitoylprotein. 
2.1.4 Depalmitoylation 
While several different palmitoyl transferases have been identified recently, current 
knowledge of depalmitoylating enzymes is somewhat limited (Huang and El-
Husseini 2005). So far, only two enzymes possessing depalmitoylation activity on 
proteins, acyl protein thioesterase 1 (APT1) and palmitoyl protein thioesterase 1 
(PPT1) (Lu and Hofmann 2006), the subject of this thesis, are known. PPT2, a 
homolog of PPT1, cleaves thioester bonds from linear molecules such as S-
palmitoyl-CoA, but is unable to cleave palmitate from substrates with bulky head 
groups such as palmitoylated proteins (Calero et al. 2003). While PPT1 has been 
shown to function in lysosomes (Lu et al. 1996), APT1 operates in the cytosol 
(Duncan and Gilman 1998). It is worth mentioning that when APT1 was purified 
from rat liver, no palmitoyl thioesterase activity against palmitoyl-G was detected 
other than those derived from PPT1 and ATP1 (Duncan and Gilman 1998). 
The crystal structure of APT1 has been determined and it belongs to a large family 
of / hydrolases, as does PPT1 (Devedjiev et al. 2000). APT1 is a dimer and it has 
to dissociate to reveal the substrate binding site. APT1 removes palmitate from 
several substrates in vitro, including H-Ras, Gs, and endothelial nitric oxide 
synthase (eNOS) (Yeh et al. 1999). Depalmitoylation of these proteins by APT1 is 
more efficient when the substrates are activated (Smotrys and Linder 2004). APT1 
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deficiency in humans has not been reported, but yeast apt1 null cells grow normally 
and do not show defects in lipid metabolism although they lack acyl-protein 
thioesterase activity (Duncan and Gilman 2002). In murine small intestine epithelial 
cells, overexpression of APT1 led to translocation of mutant Gs (involved in a 
neonatal diarrhea phenotype) from the plasma membrane to the cytosol and reduced 
cAMP levels (Makita et al. 2007). Interestingly, based on the sequence in mass 
spectrometry, another acyl-protein thioesterase APT2 was reported to be associated 
with membranes and especially lipid rafts in HeLa cells, but its function in vivo has 
not yet been reported (Foster et al. 2003). 
2.1.5 Palmitoylation and neuronal function 
Protein palmitoylation is especially abundant in neurons. It is involved in a variety 
of neuronal functions, including neuronal development, synapse maturation, signal 
transduction, and intracellular trafficking. The dynamic nature of palmitoylation is 
particularly important in neurons, providing means to respond rapidly to external 
stimuli, and in controlling neuronal growth, differentiation, and plasticity. The first 
axonal palmitoylprotein described was the growth-associated protein 43 (GAP-43), a 
cytosolic phosphoprotein interacting with the actin cytoskeleton and regulating the 
outgrowth and pathfinding of axons (Skene and Virag 1989, Strittmatter et al. 1992). 
GAP-43 possesses two S-palmitoylations near the amino terminus, enabling the 
protein’s attachment to the growth cone plasma membrane and regulating its 
function as a modulator of the G-protein signalling cascade (Sudo et al. 1992). 
Synapse maturation is induced by a specific decrease in the palmitoylation of GAP-
43 and other growth cone proteins at the beginning of the critical period of synaptic 
rearrangement (Patterson and Skene 1999). On the postsynaptic side of excitatory 
synapses, a scaffolding molecule, postsynaptic density-95 (PSD-95) protein, is 
needed for the correct assembly of AMPA-type glutamate receptors and cell 
adhesion molecules (Kim and Sheng 2004). The dual palmitoylation of PSD-95 at 
its N-terminal end is required for its targeting and clustering at the postsynaptic 
density (Craven et al. 1999). Synaptic activity regulates the palmitate turnover of 
PSD-95; agonist-stimulated depalmitoylation of PSD-95 enhances AMPA receptor 
internalization (El-Husseini Ael et al. 2002) and disruption of PSD-95 
palmitoylation blocks synaptic strengthening (Ehrlich and Malinow 2004). 
Neuronal signal transduction is initiated by the release of neurotransmitters, which 
bind to their receptors and activate downstream effectors. Synaptic vesicles, 
containing neurotransmitters, release their cargo to the synaptic cleft upon fusion 
with the presynaptic plasma membrane in a process called exocytosis. Several 
presynaptic proteins controlling synaptic vesicle exocytosis are palmitoylated, 
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including synaptotagmin I, the calcium sensor for neurotransmission, and the 
SNARE proteins VAMP (vesicle associated membrane protein) and SNAP25 
(synaptosome associated protein 25), which regulate membrane fusion. 
Palmitoylation controls the axonal targeting of synaptotagmin I, while 
palmitoylation of SNAP25 is needed for its function in synaptic vesicle dissociation 
but not for its targeting (Heindel et al. 2003, Washbourne et al. 2001). 
Neurotransmitters such as GABA (-aminobutyric acid), glutamate, dopamine, and 
serotonine all signal through G-protein coupled receptors. Similarly to the 
previously mentioned G proteins, many of the receptors coupled to them are also 
palmitoylated. For example, yeast-two-hybrid studies showed that a DHHC-protein 
GODZ palmitoylates the GABAA receptor and regulates its clustering to the 
postsynaptic membrane (Keller et al. 2004). Palmitoylation is important not only for 
targeting the receptor to specific membrane domains (Qanbar and Bouvier 2003), 
but depending on the receptor, it also up- or downregulates downstream G-protein 
signalling (el-Husseini Ael and Bredt 2002). 
An example of severe neuronal dysfunction caused by the disruption of protein 
palmitoylation is the autosomal dominant Huntington’s disease, characterized by 
involuntary body movements (chorea) and cognitive disability. It is caused by 
polyglutamine (CAG) repeat expansions in the huntingtin gene, making the encoded 
huntingtin protein prone to aggregation (Landles and Bates 2004). Huntingtin, 
among many other neuronal proteins, was found to be palmitoylated by the DHHC-
protein HIP14 (huntingtin interacting protein 14) (Huang et al. 2004). Huntingtin 
functions in microtubule-mediated transport, specifically enhancing the trafficking 
of vesicles containing brain-derived neurotrophic factor (BDNF) (Gauthier et al. 
2004). Palmitoylation regulates the intracellular trafficking and function of 
huntingtin, and mutations expanding the polyglutamine tract disturbed the 
interaction between huntingtin and HIP14, and resulted in decreased palmitoylation 
and increased the aggregation of huntingtin (Yanai et al. 2006). Palmitoylation and 
its regulation have been proven to be vital for the function of many neuronal 
proteins, and understanding the involved mechanisms will help to elucidate neuronal 
events in health and disease. 
2.2 LYSOSOMES 
2.2.1 Intracellular membrane transport 
Eukaryotic cells are compartmentalized into several membrane-bound organelles 
with distinct functions and unique protein and lipid compositions. These organelles 
are linked to each other by constant trafficking, where vesicles bud from one 
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compartment and fuse with another. In order to achieve and maintain these highly 
specified compartments, a strictly controlled transport system has developed to 
select the soluble protein cargo, the bilayer of lipids, and the membrane proteins of 
the transport vesicle. Similarly, the uptake of the cargo at its destination is tightly 
regulated. Independent of the cellular location, vesicular trafficking consists of five 
elementary steps: 1) sorting of proteins and lipids to be transported, 2) vesicle 
formation, 3) vesicle transport along cytoskeletal filaments, 4) target organelle 
recognition, and 5) vesicle fusion with the target organelle. Proteins often require 
“address labels” to be correctly targeted, while lipids seem to hold the information 
about their target in their structure (Bonifacino and Glick 2004, Mellman and 
Warren 2000, Olkkonen and Ikonen 2000, Roux et al. 2005). Disturbances in the 
transport machinery underlie at least 30 human diseases. Most of them exhibit a 
neurological phenotype and specifically concern the movement of vesicles along the 
cytoskeletal tracts. This emphasises the importance of intracellular membrane 
trafficking for the correct function of neurons, and suggests membrane trafficking to 
have redundancy in most cell types (Olkkonen and Ikonen 2006). 
Intracellular membrane trafficking consists of two main pathways; the secretory or 
the biosynthetic pathway, and the endocytic pathway (Figure 3). The constitutive 
secretory pathway is used for the secretion of produced compounds (proteins, lipids, 
and carbohydrates) from the endoplasmic reticulum (ER) and Golgi complex to the 
cell surface and extracellular space. The secretory pathway is also used for targeting 
the products to endosomes and lysosomes via the Golgi complex. The endocytic 
pathway covers internalization of macromolecules, for example proteins, ligands, 
and receptors, as well as solutes and pathogens. After internalization, the cargo is 
transported to early endosomes, from where it can be recycled back to the cell 
surface via recycling endosomes. Cargo can also enter the degradative pathway and 
be transported to multivesicular bodies, late endosomes, or lysosomes. The secretory 
and endocytic pathways are connected via the Golgi complex and the endocytic 
compartments (Bonifacino and Rojas 2006, Nickel and Wieland 1998, van der Goot 
and Gruenberg 2006). 
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Figure 3. Pathways of intracellular membrane transport. The secretory pathway (red 
arrows) transports cargo from the endoplasmic reticulum (ER) through the 
Golgi complex to the plasma membrane or to the endocytic organelles. Cargo 
internalized from the extracellular space (blue arrows) enters the early 
endosomes and may be recycled or transported to late endosomes and lysosomes. 
The two pathways are connected at the level of the Golgi complex and the 
endosomal organelles. Figure modified from (Olkkonen and Ikonen 2000). 
2.2.2 Structure and function of lysosome 
Upon their discovery, lysosomes (Greek for digestive body) were classified as acid 
hydrolase-rich membrane-limited granules (De Duve et al. 1955). Indeed, the 
terminal degradation of proteins and lipids occurs in lysosomes, but over 50 years of 
research has proved that lysosomes are also physiologically important in other 
functions than merely catabolism. These include, for example, surface receptor 
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downregulation, release of endocytosed nutritients, and inactivation of pathogens 
(Eskelinen et al. 2003). 
The limiting membrane of the lysosome contains special features important for its 
function. Low lysosomal pH (<5) is necessary for the activation of most lysosomal 
degradative enzymes, and it is gained and maintained through an active pumping of 
protons into the organelle by a multimeric transmembrane protein, the vesicular (v-) 
H+-ATPase. The v-H+-ATPase also mediates the information about intravesicular 
pH to the cytosolic surface of the vesicle, which in turn is important for the 
maturation and trafficking of endosomes (Marshansky 2007). The lysosome-
associated membrane proteins (LAMPs) 1 and 2 make up about 50% of all proteins 
ín the lysosomal membrane. They are highly glycosylated and, together with LIMPs 
(lysosomal integral membrane proteins) and other glycosylated membrane proteins, 
they form a protective glycocalyx intralumenally on the limiting membrane. 
Emerging data suggest that they have other functions as well; for example LAMPs 
are required for the fusion of lysosomes and phagosomes (Huynh et al. 2007) and 
LIMP-2 has recently been shown to function as a receptor for lysosomal targeting 
(Reczek et al. 2007). Other, minor lysosomal membrane proteins are responsible for 
the transport of metabolites such as sugars, amino acids, cholesterol, and metals 
across the lysosomal membrane to cytosol. 
The lysosomal degradation of macromolecules occurs in a sequential manner and 
involves the action of over 50 hydrolytic enzymes and associated proteins (Sleat et 
al. 2005). For example, the degradation of glycans linked to glycoproteins takes 
place in several sequential steps, all catalyzed by specific enzymes (Winchester 
2005). The degradation of membrane lipids occurs on the surface of intra-endosomal 
and intra-lysosomal vesicles which are formed after inward budding of the limiting 
membrane (Figure 4) (Hopkins et al. 1990). Membranes to be digested are 
cholesterol-poor compared to the limiting membrane, and rich in negatively charged 
bis(monoacylglycero)phosphate (BMP), also known as lysobisphosphatic acid 
(LBPA) (Mobius et al. 2003). While other lipids (e.g. phospholipids) do not need 
cofactors for their degradation, glycosphingolipids require sphingolipid activator 
proteins (SAPs), namely saposins and the GM2-activator protein, in order to be 
degraded. Glycosphingolipids, composed of ceramide and a hydrophilic 
oligosaccharide chain, are an essential part of the outer leaflet of the plasma 
membrane. In neuronal cells, glycosphingolipids containing sialic acid (ganglio-
series) are abundant, while oligodendrocytes are rich in galactosylceramide (Kolter 
and Sandhoff 2005). Saposins A, B, C, and D are small ~80-aa lysosomal 
glycoproteins derived from a common precursor protein called prosaposin. They 
stimulate specific lysosomal sphingolipid hydrolases including ceramidases, 
arylsulfatase A, sphingomyelinase, and galactosidase (Kishimoto et al. 1992). They 
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also have lipid transfer activity in vitro and they participate in immunological events 
by loading antigenic lipids to CD1 proteins (Kang and Cresswell 2004). 
 
Figure 4. Schematic representation of membrane digestion in lysosomes. 
Glycosphingolipids are shown on the plasma membrane and on internal 
membranes. The intra-endosomal membranes act as platforms for the 
degradation of glycosphingolipids. The inner face of the lysosomal limiting 
membrane is protected from degradation by a glycocalyx. Figure modified 
from (Kolter and Sandhoff  2005). 
2.2.3 Lysosomal targeting of soluble proteins 
Lysosomes receive cargo from the secretory, endocytic, autophagic, and phagocytic 
membrane transport pathways (Luzio et al. 2007). Intracellular transport of newly 
synthesized proteins from the secretory pathway to the endocytic pathway, via the 
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endosomes to the lysosomes, is probably the best characterized (Kornfeld and 
Mellman 1989). Synchronously with their synthesis, soluble lysosomal proteins are 
translocated to the ER, where their signal sequence is cleaved and they are folded 
and glycosylated at the asparagine residues. From the ER, the proteins are targeted 
to the Golgi complex, where the oligosaccharides are trimmed and they receive the 
specific carbohydrate modification for lysosomal targeting, the mannose 6-
phosphate (Man-6-P). Man-6-phosphorylation occurs in two steps: First, N-
acetylglucosamine-1-phosphotransferase adds a N-acetylglucosamine-phosphate 
group to the mannose residues, followed by cleavage of the N-acetylglucosamine 
from the phosphate by N-acetylglucosamine-1-phosphodiester -N-acetylglucos-
aminidase (Hasilik et al. 1981, Waheed et al. 1981). 
In the trans-Golgi network (TGN), mannose 6-phosphorylated proteins are 
recognized by one of the two Man-6-P receptors (MPRs), the cation-dependent 46 
kDa MPR (CD-MPR) or the cation-independent 300 kDa MPR (CI-MPR). MPRs, 
together with their ligands, are packed into clathrin-coated vesicles. Clathrin adaptor 
protein 1 (AP-1) and GGAs (Golgi-localized, -ear-containing, ADP ribosylation 
factor-binding proteins) are needed to sort the MPR to the clathrin vesicles in the 
TGN (Doray et al. 2002). After transport and uncoating, the intermediate vesicles 
fuse with the target organelle, an early or late endosome. A subsequent decrease in 
pH facilitates MPR ligands to dissociate from their receptors, and the MPRs are 
transported back to the TGN while the protein cargo reaches the lysosomes by the 
fusion of late endosomes and lysosomes (Luzio et al. 2007). Lysosomes lack both 
MPRs, differing thus from endosomes. Around one third of the MPRs in the cell are 
present at the plasma membrane, and are capable of binding to mannose 6-
phophorylated proteins secreted either from the same or adjacent cells. MPRs and 
their ligands are endocytosed with the help of clathrin and AP-2 adaptor protein 
from the plasma membrane (Le Borgne and Hoflack 1998). 
A second route to lysosomes for newly synthesized soluble hydrolases was detected 
in I-cell disease (mucolipidosis II) patient cells, where the N-acetylglucosaminidase-
1-phosphotransferase enzyme is defective and lysosomal hydrolases do not receive 
the Man-6-P label needed for MPR recognition (Reitman et al. 1981). While most 
lysosomal proteases became secreted, nearly half of the normal amount of cathepsin 
D was still detected in the lysosomes of the patient cells (Glickman and Kornfeld 
1993). The protein responsible for the MPR-independent lysosomal sorting was later 
found to be sortilin, a multi-ligand transmembrane Golgi protein similar to MPR. 
Sortilin also sorts other lysosomal proteins such as sphingolipid activator proteins 
(SAPs) to lysosomes (Lefrancois et al. 2003). It is involved in other cellular 
functions as well, as it mediates lipoprotein lipase degradation and translocates to 
the plasma membrane from GLUT4 glucose transporter-containing vesicles after 
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insulin-stimuli (Morris et al. 1998, Nielsen et al. 1999). A third sorting pathway to 
lysosomes was recently found for -glucocerebrosidase, for which the lysosomal 
targeting signal was long unknown (Reczek et al. 2007). Lysosomal membrane 
protein LIMP-2 was found to bind with -glucocerebrosidase already in the ER and 
target the proteins to lysosomes. The ER-retention mutant of -glucocerebrosidase 
was also able to traffic to lysosomes when LIMP-2 was overexpressed.  
2.2.4 Lysosomal storage disorders affecting the central nervous system 
Lysosomal storage disorders (LSDs) are characterized by the intra-lysosomal 
accumulation of undegraded metabolites, caused by the disrupted function of 
lysosomal proteins. Over 40 LSDs are known, and most of them are caused by the 
deficiencies of soluble lysosomal hydrolases. Lysosomal transporters and integral 
membrane proteins are also involved, as are proteins that reside earlier in the 
secretory pathway and which affect the transport and maturation of lysosomal 
proteins (Futerman and van Meer 2004, Tardy et al. 2004). LSDs are often classified 
according to the main storage compound (e.g. sphingolipidoses and 
mucopolysaccharidoses). However, in some cases this has been misleading – for 
example, I-cell disease was first classified as mucolipidosis, although the defect is in 
the transport of lysosomal enzymes rather than in lipases themselves. The affected 
cellular pathways that underlie the cellular damage in LSDs are mostly unknown, as 
is the role of storage itself in the disease course. 
LSDs present variable disease phenotypes, ranging from infantile to adult forms. In 
the more severe infantile forms neurological symptoms are often prominent, 
whereas peripheral dysfunction dominates in adult forms (Futerman and van Meer 
2004). Neuronal ceroid lipofuscinoses, discussed later in this thesis, are LSDs 
characterized by severe neurodegeneration. An example of another LSD showing 
neurological manifestations is mucolipidosis type IV (MLIV), which is enriched in 
the Ashkenazi Jewish population. The symptoms include psychomotor retardation 
and ophthalmologic abnormalities. Mutations in the mucolipin-1-encoding gene 
MCOLN1 result in the lysosomal accumulation of lipids together with water-soluble 
substances (Bargal et al. 2000). Mucolipin-1 is a cation channel and its dysfunction 
is suggested to lead to abnormal endocytosis and lysosomal maturation (Bach 2005, 
Zeevi et al. 2007). The lysosomal accumulation of free sialic acid results in two 
phenotypically different diseases with neurological manifestations, a severe infantile 
sialic acid storade disease (ISSD) and a slowly progessing adult form, Salla disease, 
which is enriched in Finland. Both diseases are caused by mutations in the SLC17A5 
gene, disrupting the function of sialin, an anion transporter residing in the lysosomal 
membrane (Verheijen et al. 1999). 
 27 
LSDs are monogenic disorders, but the type of mutation and its location in the 
affected gene may vary. When the mutated protein is an enzyme, there can be some 
correlation between the residual enzyme activity and the disease phenotype 
(Gieselmann 2005). However, the phenotype can rarely be predicted based on the 
genotype. Sometimes the same mutation can result in exact opposite phenotypes, as 
is the case in Gaucher disease, a sphingolipodosis caused by mutations in -
glucocerebrosidase. An individual diagnosed with Gaucher disease can suffer from 
severe disease, while another individual with the same genotype may be 
asymptomatic (Beutler 2007). The reason for the phenotypic variance is not known, 
but environmental factors as well as modifying genes have been suggested to 
influence the clinical course. 
2.2.5 Lysosomal proteins functioning outside lysosomes 
Some lysosomal proteins have been shown to also operate extralysosomally. These 
include cathepsin D, the lysosomal protease defective in congenital NCL (Siintola et 
al. 2006), and -hexosaminidase A, the enzyme disrupted in Tay-Sachs disease 
(Beutler et al. 1975). Cathepsin D is synthesized as a prepropeptide and is 
proteolytically modified into its active form. The pre-peptide acts as a signal 
sequence and is removed after translocation to the ER. Procathepsin D is inactive, 
until the pro-peptide is cleaved in the endosomal or lysosomal compartments 
(Erickson et al. 1981). The increased secretion of the inactive pro-enzyme has been 
implicated in many types of cancer, presumably enhancing the proliferation, 
invasion, and metastasis of cancer cells (Fusek and Vetvicka 1994). The pro-peptide 
has been shown to possess mitogenic activity, being independent of MPR but 
functioning through some yet undefined cell surface receptor (Ohri et al. 2008). An 
additional role for a lysosomal enzyme, independent of its activity or correct 
lysosomal trafficking, is thus present in paracrine signalling. 
-hexosaminidase A and B are isoenzymes cleaving glucosamine- and 
galactosamine-N-acetyl residues from oligosaccharides, glycoproteins, and 
glycolipids. -hexosaminidase A (Hex A) can specifically cleave GM2 ganglioside, 
concentrated in lipid rafts and on the neuronal cell surface, in the presence of 
sphingolipid activator protein GM2-activator (Wendeler et al. 2004). Hex A is 
mainly found as a soluble enzyme inside the lysosomes where it is targeted via the 
MPR pathway and processed into its mature form (Mahuran 1999). A recent study 
reports 3-5% of mature Hex A to be present on the cell surface, as shown by cell 
surface biotinylation and activity assays (Mencarelli et al. 2005). This finding 
suggests an exchange of Hex A via a direct fusion between lysosomes and plasma 
membrane, a phenomenon described for example in plasma membrane repair 
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(Reddy et al. 2001). In addition, the Hex A enzyme was found to be membrane-
associated, although no structural evidence for this is found in the enzyme itself. 
Hex A may thus have a role outside lysosomes, for example possibly being capable 
of modifying the lipid composition of the outer leaflet of the neuronal plasma 
membrane and thus further influencing the signalling processes of the cell. These 
findings highlight the importance of the possible additional functions of lysosomal 
enzymes in physiological and pathological processes and may in part explain the 
phenotypic variance seen in many LSDs. 
2.3 CENTRAL NERVOUS SYSTEM AND CHOLESTEROL 
METABOLISM 
2.3.1 Brain and cholesterol homeostasis 
Brain tissue is composed of signalling nerve cells, or neurons, and glial cells, 
namely astrocytes, oligodendrocytes, and microglia. Glial (Greek for glue) cells, 
comprising ~90% of the total cell count in the central nervous system (CNS), were 
initially thought to be the “connective tissue” of the brain (Gray 1918). Today, glial 
cells are known to be more versatile and they have proven to be an essential part of 
the correct functioning of the nervous system. Oligodendrocytes provide insulation 
for the electricity-conducting axons of neurons by forming a myelin sheath around 
them (Simons and Trotter 2007). Microglia are the “immune system of the brain” 
and respond to brain injury and immunological stimuli (Hanisch and Kettenmann 
2007). Astrocytes regulate blood flow in the brain, modulate synaptic function, and 
transport nutritients to neurons (Maragakis and Rothstein 2006, Voutsinos-Porche et 
al. 2003). They are also central players in the cholesterol metabolism of the CNS 
(Mauch et al. 2001). Systemic cholesterol metabolism has been widely studied 
because of its well-established role in atherosclerosis. Cholesterol metabolism in the 
CNS, however, has only recently been elucidated. Cholesterol, together with 
phospholipids, is an essential lipidous part of the plasma membrane in human cells. 
The CNS is particularly rich in cholesterol, and the cholesterol concentration in the 
brain is around ten times higher than in other organs. Most of the cholesterol in the 
CNS is stored in myelin, as myelin is composed 70% of lipids enriched with 
cholesterol and galactosylceramide (cerebroside) (Simons and Trotter 2007). While 
cholesterol in other parts of the body can either be synthesized de novo or taken up 
from plasma, the CNS is isolated from plasma cholesterol supplies by the blood-
brain barrier (BBB) and is self-sustaining in cholesterol (Dietschy and Turley 2001). 
The rate of cholesterol synthesis in the brain during development follows the 
production of myelin by oligodendrocytes, which is highest during the first 4 weeks 
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of life in mice (the first and early second years of life in the human) (Brody et al. 
1987). The rate of cholesterol synthesis declines after myelination, but remains at a 
steady level, reflecting synthesis in other parts of the CNS (Dietschy and Turley 
2004). Excess cholesterol in the brain is removed by converting it to 24(S)-
hydroxycholesterol, which is able to cross the BBB (Lutjohann et al. 1996). 
Cholesterol 24-hydroxylation is performed by the enzyme CYP46A1, which resides 
exclusively in neurons (Lund et al. 1999). 
2.3.2 Lipoproteins in plasma and cerebrospinal fluid 
Lipoproteins are macromolecular complexes composed of lipids and proteins called 
apolipoproteins. In plasma, they transport lipids from one part of the body to 
another, providing peripheral cells with energy, precursors to steroids, and material 
for membrane synthesis. They also transport lipids from peripheral cells especially 
via the HDL-facilitated pathway called reverse cholesterol transport, whereby 
cholesterol enters the liver for excretion or for use in bile acid synthesis. Lipoprotein 
particles are composed of a neutral lipid core containing triacylglycerols and 
esterified cholesterol, and a polar surface composed of phospholipids and 
apolipoproteins. Lipoprotein particles are traditionally classified according to their 
densities, and named consequentially: HDL, or high-; LDL, or low-; and VLDL, or 
very low-density lipoprotein. These three classes are the major ones found in the 
circulation. Basically, the more neutral lipids the particle carries, the lower the 
density. Apolipoproteins play a central role in lipoprotein metabolism. They are 
located on the surface of the particle and are capable of binding to receptors on the 
cell surface, directing lipoprotein metabolism. They are also important cofactors for 
some key enzymes in lipid metabolism (Danik et al. 1999, Gotto et al. 1986). In 
addition to plasma, lipoproteins are found also in cerebrospinal fluid (CSF), where 
they transport lipids between different cell types of the nervous system. The 
lipoproteins in CSF differ from those in plasma in size and apolipoprotein 
composition. In plasma, the main lipoprotein particles are spherical and the major 
apolipoproteins linked to VLDL are apoB-100 and apoE, whereas LDL is mostly 
linked to apoB-100 and HDL to apoA-I. The main apolipoproteins in CSF are apoE, 
apoJ and apoA-I, and the HDL-like lipoprotein particles are discoidal and smaller 
than those in plasma (Koch et al. 2001, Legleiter et al. 2004). ApoE is synthesized 
mainly by astrocytes (Pitas et al. 1987) and microglia (Nakai et al. 1996), whereas 
apoA-I is not synthesized in the CNS. It is thought to either cross the BBB via 
transcytosis through capillary endothelial cells or to be synthesized by these cells 
(Kratzer et al. 2007, Panzenboeck et al. 2002). 
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2.3.3 Cholesterol transport in the CNS 
Although current knowledge about cholesterol trafficking inside the CNS is limited, 
many proteins involved in plasma cholesterol metabolism are also expressed in the 
CNS, suggesting the existence of similar pathways. In addition to apolipoproteins 
(mainly apoE) expressed by astrocytes, the CNS cells also express lipoprotein 
receptors belonging to the LDL receptor (LDLR) family. These structurally related 
receptors have diverse functions and ligands, being involved in Wnt and Reelin 
signalling and intracellular transport in addition to their function in cholesterol 
transport (Cam and Bu 2006). The LDLR family consists of over 10 members, 
including LDLR, VLDLR, LRPs (LDL receptor –related proteins), apoER2, sorLA 
(sortilin–related receptor containing LDLR class A repeats, also called LR11), and 
they all bind apoE. Neurons express many of these receptors, especially LRP1, 
VLDLR, apoER2, and sorLA (Andersen and Willnow 2006), whereas astrocytes 
express mostly LDLR (Rapp et al. 2006). ATP-binding-cassette transporters (ABC 
transporters), involved in the transport of lipids and other substances across the 
membranes, are also expressed in different cell types of the CNS. Especially ABCA1, 
ABCA2, ABCG1, and ABCG4 are abundant in the brain (Kim et al. 2008). 
Transmembrane ABC transporters differ in their intracellular localization and the type 
of transported lipids, as well as in the type of the lipid acceptor protein. ABCA1, 
residing mostly in the plasma membrane, mediates cholesterol efflux from neurons to 
the lipid-poor apoE and apoE-phospholipid discs (Kim et al. 2007). Endo/lysosomal 
ABCA2 is mostly expressed by oligodendrocytes and is involved in intracellular 
sphingolipid transport and myelin maturation (Sakai et al. 2007). Vesicular ABCG1 
and ABCG4 stimulate cholesterol efflux and mediate intracellular cholesterol transport 
in neurons and astrocytes (Tarr and Edwards 2008, Wang et al. 2004). 
Like other cells, neurons also are able to synthesize cholesterol. During 
synaptogenesis, however, they are dependent on external cholesterol from glia-
derived apoE-containing lipoproteins. Cholesterol increases the number of formed 
synapses and its function is inhibited by blocking the members of the LDLR family 
(Mauch et al. 2001). More specifically, cholesterol has been found to directly 
promote maturation of the presynaptic terminals and to be important in dendrite 
differentiation (Goritz et al. 2005). It was later also found that not all neurons are 
alike; while retinal ganglion cells need glia for synapse formation, hippocampal and 
cerebellar neurons efficiently form synapses without astrocytes (Steinmetz et al. 
2006). Also, excitatory synapses are enhanced by glial cholesterol in all neuron 
types, while it has no effect on inhibitory synapses. Studies on hippocampal 
astrocytes and neurons showed that neurons are more dependent on the apoE-bound 
cholesterol than astrocytes, and apoE-derived cholesterol was associated with 
membranes significantly more in neurons than in astrocytes (Rapp et al. 2006). 
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ApoE expression is also strongly increased during regeneration followed nerve 
injury, further indicating its essential role in the membrane repair of neurons (Poirier 
et al. 1993). 
2.3.4 Cholesterol and neurodegenerative diseases 
The importance of cholesterol metabolism for CNS function is underlined by its 
connection with severe neurological diseases such as Alzheimer’s disease (AD) and 
Niemann-Pick type C (NPC). AD is characterized histopathologically by the 
formation of extracellular amyloid plaques composed of -amyloid peptide (A) and 
intracellular neurofibrillary tangles consisting of abnormally phosphorylated tau 
protein. A is formed by the sequential proteolytic cleavage of the amyloid 
precursor protein (APP) by - and -secretases (Kang et al. 1987, Zhang and Xu 
2007). The link between AD and cholesterol was first noted in population-based 
studies when the APOE4 isoform was found to be associated with increased risk of 
late-onset AD (Saunders et al. 1993, Schmechel et al. 1993). Hypercholesterolemia 
itself was found to be an independent risk factor for AD (Kivipelto et al. 2001), and 
cholesterol is needed for A formation in hippocampal neurons (Simons et al. 1998). 
Therefore statins, drugs that inhibit HMG-CoA (3-hydroxy-3-methylglutaryl-
coenzyme A) reductase activity and reduce cholesterol synthesis, have been studied 
in the prevention of AD; however, the results have been controversial (Canevari and 
Clark 2007). At the moment it is not evident how apoE4, cholesterol, and the 
development of AD are interconnected, but intensive research has revealed many 
contributing cellular mechanisms. Cholesterol bound to the apoE4-phospholipid 
complexes could not be taken up by neurons as efficiently as cholesterol bound to 
other apoE isoforms (Rapp et al. 2006). When apoE-containing lipoproteins were 
shown to protect CNS neurons from apoptosis by the LRP-receptor-mediated 
pathway, apoE4 was less protective than apoE3 (Hayashi et al. 2007). ApoE is also 
important for the A clearance (Ladu et al. 2000). Many LDLR family members 
have been shown to interact with APP and regulate its endocytic processing, thus 
influencing the formation of A (Cam and Bu 2006). The role of lipids other than 
cholesterol in AD has also been implicated. Sphingomyelin prevented A formation 
and sphingomyelinase activity is increased in some familial forms of AD (Grimm et 
al. 2005). A diet rich in polyunsaturated fatty acids, for example regular fish 
consumption, decreases the risk of AD (Morris et al. 2003). At least one reason for 
this has been reported: omega-3 fatty acid docosahexaenoic acid (DHA), present in 
fish oil, significantly increased the expression of SorLA, a LDLR protein involved 
in A reduction (Ma et al. 2007). 
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NPC is an autosomal recessive lysosomal storage disorder caused by mutations in 
two genes, NPC1 and NPC2 (Carstea et al. 1997, Naureckiene et al. 2000). The 
precise functions of the NPC proteins are not known, but they are thought to have a 
role in intracellular cholesterol transport as the disease is characterized by the  
accumulation of free cholesterol, bis(monoacylglycero)phosphate (BMP), and 
sphingolipids in the endo/lysosomal compartments of the cell (Ikonen and Holtta-
Vuori 2004). Clinical symptoms are diverse, but neurological impairment is one of 
the disease hallmarks. Npc1-deficient glial cells accumulate cholesterol, but their 
function appears normal and they generate normal apoE-containing lipoproteins. In 
Npc1-deficient neurons, however, the distribution of intracellular cholesterol is 
altered, and cholesterol transport from the cell soma to axons is inhibited (Vance et 
al. 2006). Cholesterol and sphingolipids are both typical components of lipid rafts 
and NPC1 has been shown to participate in the depletion of lipid rafts from late 
endocytic organelles (Lusa et al. 2001). It has been suggested that cholesterol 
accumulation could actually be secondary to sphingolipidosis, as sphingolipids are 
the primary storage compound in neurons and are needed for cholesterol 
accumulation (Gondre-Lewis et al. 2003). 
2.4  NEURONAL CEROID LIPOFUSCINOSES 
2.4.1 Common features in NCLs 
Neuronal ceroid lipofuscinoses (NCLs) are a group of autosomal, recessively 
inherited progressive encephalopathies with an estimated incidence of 1:12 500 in 
the United States (Rider and Rider 1988). The diseases can have congenital, 
infantile, late infantile, juvenile, or adult onset. The childhood forms present the 
majority of NCLs, and NCLs are considered to constitute the most common group of 
neurodegenerative diseases in children worldwide (Haltia 2003). The early-onset 
diseases share similar clinical symptoms such as loss of vision, mental and motor 
deterioration, epileptic seizures, and premature death (Santavuori et al. 2000). The 
first symptoms in adult NCLs are usually cognitive impairment and early dementia 
(Hinkebein and Callahan 1997, van Diggelen et al. 2001). Symptoms result from 
severe neuronal death occurring mainly in the cerebral and cerebellar cortices. 
In addition to neurodegeneration, histopathological findings are also common to all 
NCL subtypes. Neurons, and many other cell types, accumulate autofluorescent 
storage material called ceroid-lipofuscin (Zeman and Dyken 1969). Storage deposits 
are resistant to lipid solvents and their ultrastructural phenotype is an important 
classification method before possible genetic tests (Goebel 1997). In most NCLs, 
over 50% of the storage material consists of subunit c of the mitochondrial ATP 
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synthase (Palmer et al. 1992). In infantile and congenital NCLs the main storage 
compounds are sphingolipid activator proteins (SAPs) (Tyynela et al. 1993). The 
main stored compound seems to determine the storage ultrastructure – SAPs are 
associated with GROD-like structures (granular osmiophilic deposits), while the 
storage of subunit c of ATP synthase results in more variable forms of curvilinear, 
rectilinear, or fingerprint patterns (Haltia 2006). 
To date, over 200 mutations in eight different genes have been identified behind the 
NCL diseases (CLN1, CLN2, CLN3, CLN5, CLN6, CLN7, CLN8 and CLN10/CTSD) 
(NCL Resource database, http://www.ucl.ac.uk/ncl/mutation.shtml, S. Mole) 
(Siintola et al. 2007, Siintola et al. 2006) and they serve as the basis for the current 
NCL classification. A summary of the genes and the disease phenotypes, affected 
proteins, storage material, and ultrastructure related to them are shown in Table 1. 
INCL and vLINCLFin, caused by mutations in the CLN1 and CLN5 genes, 
respectively, are discussed later in more detail. 
2.4.2 NCLs in animals 
NCLs are not merely a human disease, as different NCLs also affect many animals. 
These include sheep, with mutations in the CTSD, CLN5, and CLN6 genes (Broom 
et al. 1998, Frugier et al. 2008, Houweling et al. 2006, Tyynela et al. 2000). Dogs 
are affected with mutations in CLN2, CLN8, CLN5, and CTSD (Awano et al. 2006a, 
Awano et al. 2006b, Katz et al. 2005, Melville et al. 2005b). Cattle with the CLN5 
mutation have also been reported (Houweling et al. 2006). Cats, pigs, birds, and 
horses have been reported to suffer from NCL as well (Goebel et al. 1999). A 
naturally occurring large animal model with PPT1 deficiency remains to be 
characterized. 
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Table 1. Classification of the NCLs. Disease phenotypes, affected proteins, storage 
ultrastructure, and the main storage material are presented. GROD, granular osmiophilic 
deposits; CL, curvilinear profiles; FP, fingerprint bodies; RL, rectilinear complexes. 
Gene Disease Protein Storage ultra-structure 
Main storage 
material 
CLN1 
Infantile, also late 
infantile, juvenile 
and adult 
PPT1, palmitoyl 
protein thioesterase 
1, soluble 
GROD Saposins A and D 
CLN2 Late infantile, juvenile 
TPP1, tripeptidyl 
peptidase 1, soluble CL 
Subunit c of 
ATP synthase 
CLN3 Juvenile CLN3, transmembrane FP (CL, RL) 
Subunit c of 
ATP synthase 
CLN4 (not 
identified) Adult Not known FP, granular 
Subunit c of 
ATP synthase 
CLN5 Late infantile, Finnish variant CLN5, soluble RL, CL, FP 
Subunit c of 
ATP synthase 
CLN6 Late infantile CLN6, transmembrane RL, CL, FP 
Subunit c of 
ATP synthase 
CLN7 
(MFSD8) 
Late infantile, 
Turkish variant 
MFSD8, 
transmembrane RL, CL, FP 
Subunit c of 
ATP synthase 
CLN8 Late infantile, Northern epilepsy 
CLN8, 
transmembrane CL 
Subunit c of 
ATP synthase 
CLN9 (not 
identified) Juvenile Not known 
CL (FP, 
GROD) 
Subunit c of 
ATP synthase 
CTSD 
(CLN10) 
Congenital, late 
infantile 
CTSD, Cathepsin D, 
soluble GROD 
Saposins A and 
D 
 
2.4.3 Mitochondria and NCLs 
The role of mitochondria in the pathogenesis of NCLs has been under investigation 
for over a decade. The reason for this is the accumulation of subunit c of the 
mitochondrial ATP synthase in most NCLs. Neurons are extremely vulnerable to 
energy depletion resulting from mitochondrial dysfunction. Increasing evidence also 
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suggests that mitochondria, the important regulators of cell death, have a key role in 
the neurodegeneration of aging-related diseases via apoptosis and oxidative stress 
(Lin and Beal 2006). Additionally, mutations in mtDNA or nuclear genes encoding 
mitochondrial proteins lead to mitochondrial diseases of which neurological 
impairment is a hallmark (Zeviani and Carelli 2007). 
Subunit c of the ATP synthase accumulates in the storage deposits in 8 out of 10 
NCLs (Table 1). It is a highly hydrophobic protein locating in the inner membrane 
of mitochondria and belonging to the Fo-complex of the ATP synthase (complex V). 
Subunit c oligomerizes to form a proton channel, allowing protons to flow from the 
intermembrane space to the matrix and harnessing the energy for ATP synthesis 
produced by the F1-complex. When released, subunit c has a tendency to self-
aggregate with lipids, and once formed, these aggregates are relatively insoluble and 
protease-resistant (Elleder et al. 1995). It has been postulated that there is a specific 
problem in the catabolism of subunit c, since studies with ovine NCL showed 
neither defects in the amount or structure of subunit c in mitochondria nor defects in 
oxidative phosphorylation (Palmer et al. 1992). TPP1, the enzyme defective in 
LINCL (CLN2), has in fact been demonstrated to be associated with the degradation 
of subunit c (Ezaki et al. 1999). The activity of TPP1 is elevated in other NCLs 
accumulating subunit c, but also in INCL lacking subunit c storage (Junaid and 
Pullarkat 1999). 
Autophagy, or cellular self-eating, is a lysosomal degradation pathway for the 
cytoplasm, i.e. cytosolic proteins and organelles (Eskelinen et al. 2005). Autophagy 
has proven to be an important pathway for cell survival – not only as a way for the 
cell to adapt to starvation, but also as a part of its normal homeostasis. Disturbances 
in the autophagic processes have been postulated to be involved in the pathogenesis 
of many diseases such as cancer, infectious diseases, and neurodegenerative diseases 
(Mizushima et al. 2008). Mouse models for JNCL and congenital NCL have been 
shown to possess induced autophagy, determined by the increased amounts of LC3-
II (microtubule associated protein 1 light chain 3), an autophagosome-specific 
membrane-bound protein, in the nervous tissues of the mouse models. The 
predominance of immature autophagic structures in brain tissue was verified by cell 
fractionation and electron microscopy (Cao et al. 2006, Koike et al. 2005). 
Autophagosomes are double-membrane-bound vacuoles wrapped around cytosolic 
organelles, including mitochondria. Abnormal degradation of the autophagocytosed 
material could underlie the accumulation of subunit c with a typical storage 
ultrastructure, although the exact role of CLN3 or CTSD in autophagy is yet 
unknown. 
Morphological changes in the mitochondria have been detected in some NCL 
subtypes. Abnormal mitochondria have been reported in JNCL patients (Zeman and 
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Donahue 1963). Cultured primary neurons derived from two different Cln3-deficient 
mouse models also show enlarged mitochondria (Fossale et al. 2004, Luiro et al. 
2006). Enlarged mitochondria with abnormal cristae were also found in the 
GABAergic neurons of the English setter model for CLN8 (March et al. 1995). 
CLN6-affected sheep and Ppt1-deficient C. elegans (INCL model) show 
mitochondrial abnormalities in neurons (Porter et al. 2005, Walkley et al. 1995).  
Mitochondrial dysfunction is also reported in several NCLs. Studies have been 
conducted with CLN1, CLN2, and CLN3 human patient and CLN6 sheep fibroblasts 
(Das et al. 1999, Das et al. 1996). Regulation of the mitochondrial ATP synthase 
was measured after exposing the cells to different stimuli including anoxia and 
calcium. The anomalies in ATP synthesis varied between diseases, but they were 
present in each disease type studied. The general conclusion was that disturbances in 
ATP production could be linked to energy-linked excitotoxicity, especially in 
metabolically active neurons (Jolly et al. 2002b). In this scenario, ATP deficiency 
would first lead to insufficient plasma membrane repolarization driven by the Na+-
K+-ATPase pumps. This would further lead to the increased flow of Ca2+ in the 
cytoplasm followed by calcium-mediated neuronal death. In fact, Cln3-deficient 
mouse neurons showed slower recovery from depolarization when N-type calcium 
channels were blocked, potentially leading to Ca2+-induced excitotoxicity (Luiro et 
al. 2006). Results from studies on Ppt1-deficient mouse neurons were quite 
opposite; the knock-out neurons recovered better from the glutamate-induced 
calcium peak than the control neurons. However, many genes involved in calcium 
buffering were also upregulated in Ppt1-deficient neurons, suggesting a possible 
attempt to correct the situation (Ahtiainen et al. 2007). 
2.4.4 NCL proteins connected to lipids 
CLN3, the protein defective in JNCL, is an endo-lysosomal transmembrane protein 
with a yet undefined function (Kyttala et al. 2004). However, two recent studies 
have implicated the involvement of CLN3 in lipid metabolism. First, Narayan and 
co-workers identified a low-stringency match in the N-terminal CLN3 sequence to a 
fatty acid desaturase domain (Narayan et al. 2006). They found that the CLN3 
desaturase activity was the strongest towards palmitoylated proteins, turning 
palmitate into palmitoleic acid. This modification would affect the substrate’s ability 
to locate, for example, in highly ordered lipid rafts. A second study reported an 
association of CLN3 with BMP synthesis (Hobert and Dawson 2007). Hobert and 
co-workers noted that detergent-resistant microdomains (DRMs or lipid rafts) 
extracted from JNCL patients’ brains (autopsy samples) were less buoyant than the 
control samples. To explain this, they examined the phospholipid composition of 
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DRMs and found that BMP levels in CLN3-deficient samples were reduced to 20% 
of that of the control. JNCL patient fibroblasts and overexpression studies revealed a 
positive correlation with CLN3 expression and BMP levels. BMP, or LBPA 
(lysobisphosphatic acid), is found especially in the internal membranes of 
multivesicular late endosomes (Kobayashi et al. 1998), an organelle where CLN3 is 
also localized. LBPA is enriched in raft-like domains in the internal membranes of 
these organelles and involved in lipid and protein sorting in the 
endosomal/lysosomal system (Kobayashi and Hirabayashi 2000). Interestingly, 
Luiro and co-workers have reported defects in membrane trafficking in JNCL 
fibroblasts (Luiro et al. 2004). An LDL receptor-mediated degradative endocytosis 
experiment showed that by the endocytic time-course, LDL predominantly co-
localized with the LBPA-labeled late endosomes in wild type cells, whereas LDL 
did not reach the late endosomes but was exclusively found in the early endosomes 
in CLN3-deficient cells. The missing co-localization of LDL and LBPA could result 
from the diminished LBPA content in JNCL cells. Together, these data implicate a 
role for CLN3 in the maintenance of the characteristics of the late endosomal 
membrane, important for lysosomal maturation and degradation of lipids and 
membrane-bound proteins. It would be interesting to see whether these potential 
new functions of CLN3 could be connected to the previously reported associations 
with cytoskeletal dysfunctions (Luiro et al. 2006). 
The sequence of CLN8, an ER-Golgi–resident transmembrane protein associated 
with vLINCL and Northern epilepsy, was examined in silico and found to be 
homologous to a large protein family with a TLC domain (TRAM, Lag1, CLN8) 
(Winter and Ponting 2002). The members of this protein family are linked to the 
synthesis, transport, and sensing of lipids. CLN8 was suggested to have a possible 
role in ceramide synthesis and the transport of ceramide between the ER and Golgi. 
Indeed, liquid chromatographic and mass spectrometric analyses of two CLN8-
deficient patients’ cerebral samples revealed abnormal sphingo- and phospholipid 
levels (Hermansson et al. 2005). The analyzed patients were in different stages of 
the disease, and the lipid composition varied between them. The patient with the less 
advanced disease showed reduced levels of ceramide, galactosyl- and 
lactosylceramide, and a decrease of lipids from these sphingolipid classes containing 
long fatty acids. 
Cathepsin D, involved in congenital and late infantile NCLs, has also been linked to 
lipid metabolism. Its proteolytic activity has been suggested to be induced by 
ceramide binding (Heinrich et al. 2000). CTSD has been reported to regulate 
ABCA1-mediated lipid efflux from macrophages and CHO cells (Haidar et al. 
2006). CTSD inhibition led to over 70% reduction of apoA-I mediated lipid efflux 
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via reduced ABCA1 expression and mislocalization. Accumulation of 
glycsphingolipid and free cholesterol was detected in late endosomes/lysosomes. 
2.4.5 INCL – clinical picture 
Infantile NCL (INCL, Santavuori-Haltia disease, MIM 256730) is caused by 
mutations in the CLN1 gene, resulting in the deficiency of palmitoyl protein 
thioesterase 1 (PPT1) (Jarvela 1991, Vesa et al. 1995). INCL was described by the 
Finnish pediatrician Pirkko Santavuori and co-workes in a study of 15 patients 
(Santavuori et al. 1973). The disease is enriched in the Finnish population, with an 
incidence of 1:20 000 and a carrier frequency of 1:70. Affected newborns are 
healthy and develop normally until the first symptoms, protracted head growth and 
muscular hypotonia, are seen around the age of six months. Magnetic resonance 
imaging shows hypointense thalami in T2-weighted images very early in the course 
of the disease, even before the first clinical signs (Santavuori et al. 2001). Sleep 
problems, irritability, visual failure, ataxia, and motor clumsiness develop, and 
during the second year of life the deterioration of motor and mental development is 
rapid (Williams et al. 2006). By the age of three, the EEG of the patients is 
isoelectric and they have lost active movements and social and visual contact with 
their environment. Death usually occurs around 10 years of age. 
In addition to infantile NCL, mutations in the CLN1 gene can also result in a disease 
with delayed onset. Mutations in the CLN1 gene have been estimated to cause about 
20% of NCL cases in the US, and only half of them presented in infants (Wisniewski 
et al. 2001). Some mutations are connected to the late infantile or juvenile disease 
types, which clinically resemble other NCLs with later onset (Kalviainen et al. 2007, 
Mitchison et al. 1998, Mole et al. 2001). Interestingly, three adult cases have also been 
described. Disease onset occurs in the third or fourth decade of life and its progression 
is slow. The first signs of neurodegeneration are depression, cognitive decline, 
impaired vision, and hallucinations, later resulting in dementia, ataxia, and motor 
weakness (Ramadan et al. 2007, van Diggelen et al. 2001).  
2.4.6 Neuropathology of INCL 
The fundamental neuropathological findings in INCL were described in parallel with 
the clinical findings in the early 1970’s by the Finnish neuropathologist Matti Haltia 
(Haltia et al. 1973). Frontal brain biopsies from 1,5-year-old patients show 
progressive neuronal loss, severe astrocytic hyperplasia and hypertrophy, and 
macrophage infiltration in the cortex. All cell types contain autofluorescent storage 
granules. In older patients (3 years) the cortical neurons are almost totally lost and 
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macrophages dominate the cortex. Autopsy samples show striking generalized brain 
atrophy (Figure 5). Both the cerebral and cerebellar cortices are depleted of 
neurons, except for a few giant cells of Betz and occasional hippocampal CA1 
pyramidal cells and Purkinje cells. Hypertrophic astrocytes with coarse processes 
form a rim in the cortices. Neurons in the basal ganglia and brainstem are less 
affected, and neurons in the spine and ganglia are well preserved despite significant 
storage. In all parts of the brain, a subtotal to total loss of myelin and fibrillary 
astrogliosis is detected. 
 
Figure 5. Sagittal sections of the brains of an INCL patient (above) and a normal 
control (below). The INCL brain is severely atrophied; especically the 
volume of the cerebral cortex is diminished. Figure courtesy of Prof. Juhani 
Rapola. 
2.4.7 Intracellular storage material in INCL 
Autofluorescent lysosomal storage material with an ultrastructure of granular 
osmiophilic deposits (GROD) is characteristic to all diseases with mutations in 
CLN1, independent of the age of disease onset (Figure 6). The main protein 
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components in GRODs are saposins A and D, which seem to determine the storage 
ultrastructure (Tyynela et al. 1993). GRODs together with at least saposin D storage 
are also found in congenital NCL caused by the deficiency of cathepsin D (Siintola 
et al. 2006). Saposins are sphingolipid activator proteins derived from a common 
precursor polypeptide called prosaposin via proteolytic cleavage (discussed in 
Chapter 2.2.2). Saposin A is required for the lysosomal degradation of 
galactosylceramide (cerebroside) (Matsuda et al. 2001) and saposin D is involved in 
the degradation of ceramide (Azuma et al. 1994). Interestingly, cathepsin D is 
involved in the proteolysis of prosaposin (Hiraiwa et al. 1997). Prosaposin is widely 
expressed in various tissues, and in addition to serving as a precursor for mature 
saposins, it is secreted into various bodily fluids such as milk, bile, and semen 
(Hineno et al. 1991). In the brain, prosaposin functions as a potent neurotrophic 
factor (O'Brien et al. 1994). An alternative splicing of prosaposin is linked to brain 
development, the percentage of the longer mRNA isoform increasing during 
embryogenesis (Cohen et al. 2004). It is also linked to neuronal regeneration, as the 
expression pattern of the two mRNA forms present in the rat is changed after nerve 
injury (Chen et al. 2008, Hiraiwa et al. 2003).  
Figure 6. Electron micrograph of granular osmiophilic storage deposits (GRODs) in 
the cortex of an INCL patient (autopsy sample). Figure courtesy of Prof.  
Juhani Rapola. 
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Saposins are highly hydrophobic proteins, and in addition to INCL, they tend to 
accumulate in many other lysosomal storage disorders as well, such as type A 
Niemann-Pick, Tay-Sachs, and Gaucher disease. However, in these diseases, 
saposins accumulate together with associated sphingolipids after primary defects in 
sphingolipid metabolism (Morimoto et al. 1990), while in INCL the protein-to-lipid 
ratio is ten times higher (>1). Saposins accumulate in minor amounts also in those 
forms of NCL where the major storage protein is subunit c of ATP synthase 
(Tyynela et al. 1995). However, subunit c does not accumulate in INCL, although in 
addition to other NCLs it is also stored in many other lysosomal storage disorders.  
The cellular events leading to storage accumulation in INCL and its relation to the 
disease pathogenesis are not known. Direct interactions between saposins and PPT1 
have not been shown to occur, and saposins do not possess S-acylation. The storage 
material can already be detected in the fetus during the first trimester of pregnancy 
(Rapola et al. 1990). However, in some cases, the first symptoms of 
neurodegeneration may appear as late as in the third decade of life. This speaks for 
the hypothesis that the storage itself is not the cause of neurodegeneration. Still, 
elucidating the events behind the storage accumulation may reveal important 
mechanisms of INCL pathogenesis. In fact, abnormal processing and localization of 
saposins, possibly linked to defects in endocytosis, were recently detected in INCL 
fibroblasts and Ppt1-deficient neurons (Ahtiainen et al. 2006). In INCL fibroblasts, 
the processing of prosaposin was found to be abnormal, and prosaposin was also 
hypersecreted. The amounts of saposins A and D in INCL fibroblasts were 
significantly increased, being nearly ten times higher than in the wild type cells. 
This is interesting in the light of a study characterizising the interactions of saposins 
with model lipid bilayers using atomic force microscopy (AMF) (Alattia et al. 
2006). The authors report that saposin A forms stable and mechanically resistant 
aggregates at a protein concentration of 50μM, which is approximately ten times 
higher than normal physiological conditions. Perhaps the storage accumulation in 
INCL is due to increased concentrations of saposins A and D in the organelles of the 
endocytic pathway. Still, it is not known why the amounts of these two proteins are 
increased when at the same time the localization and concentrations of saposins B 
and C are normal in INCL cells. 
2.4.8 CLN1 gene and mutations 
The CLN1 gene (ceroid lipofuscinosis, neuronal) encoding for the PPT1 enzyme was 
identified by linkage analysis and positional cloning in chromosome 1p32 in 1995 
(Jarvela 1991, Vesa et al. 1995). CLN1 is conserved among species, having 
orthologues in vertebrates as well as in the fruit fly (Drosophila melanogaster), 
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roundworm (Caenorhabtidis elegans), and fission yeast (Schizosaccharomyces 
pombe), suggesting a fundamental cellular function for the gene (experimental 
models are discussed in Chapter 2.4.11) (Cho and Hofmann 2004, Korey and 
MacDonald 2003, Porter et al. 2005). In the human, CLN1 is a 25-kb gene 
containing 9 exons and producing a single 2.5 kb mRNA. The gene defect behind 
the classical INCL found homozygously in most Finnish cases is a missense 
mutation (c.364A>T, Arg122Trp) leading to disrupted transport and inactivity of the 
PPT1 enzyme. Other common mutations in CLN1 include two nonsense mutations 
(c.29T>A, Leu10X; c.451C>T, Arg151X) and a missense mutation (c.223A>T, 
Thr75Pro). To date, 45 disease-causing mutations have been described in the CLN1 
gene (NCL Resource database, www.ucl.ac.uk/ncl/cln1.shtml, S. Mole). Mutations 
are found throughout the gene, and most of them affect only individual families. No 
clear genotype-phenotype correlation has been observed. This may be due to small 
sample cohorts, although the possible roles of other underlying factors implicated in 
some other LSDs, such as modifier genes, remain to be studied. 
2.4.9 The PPT1 protein 
S t r u c t u r e  a n d  m o d i f i c a t i o n s  
Palmitoyl protein thioesterase (PPT1) polypeptide contains 306 amino acids, 
including a 25-aa-long N-terminal signal sequence which is cleaved co-
translationally after translocation into the endoplasmic reticulum. The crystal 
structure of bovine PPT1 (94% identical to human PPT1) has been determined by X-
ray crystallography (Bellizzi et al. 2000). The enzyme possesses a classical / 
serine hydrolase structure composed of two major domains and a catalytic triad 
(Ser115, Asp233 and His289). In the center of the molecule lies a hydrophobic fatty 
acid binding groove (Figure 7). PPT1 has three asparagine-linked glycosylation 
sites at positions 197, 212, and 232. All of them are used and shown to affect the 
activity and/or transport of the enzyme (Bellizzi et al. 2000, Das et al. 2001). 
Previous studies suggest PPT1 to exist in different biochemical environments, 
proposing possible additional modifications in PPT1. PPT1 was first described when 
investigating the palmitate cleavage of a model palmitoylated substrate, the H-Ras 
oncogene (Camp and Hofmann 1993). When different rat tissues were tested for 
depalmitoylating activity, the brain cytosolic fraction held the highest activity 
together with spleen, seminal vesicle, and testicular cytosolic fractions. However, 10 
to 25% of the activity was always associated with membranes. It is not known if 
PPT1 is partly membrane-associated, or whether the activity is derived from another 
enzyme capable of depalmitoylating H-Ras. The only enzyme described to perform 
that function is cytosolic APT1, for which membrane association has not been 
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reported (Smotrys and Linder 2004). However, similar membrane association to 
PPT1 was detected when APT1 was purified (Duncan and Gilman 1998). In 
addition, overexpressed PPT1 has been found to partly associate with detergent- 
resistant microdomains (Goswami et al. 2005). 
 
 
Figure 7. The molecular structure of PPT1. The three-dimensional structure of the 
native bovine palmitoyl protein thioesterase 1 (PPT1) complexed with 
palmitate (1EH5, Protein Data Bank, http://www.rcsb.org/pdb/). The 
polypeptide backbone structure is shown as -helices, -sheets, and coils. 
The three N-linked glycan structures (grey) on the surface of the molecule 
and the respective glycosylated asparagine amino acids (black) are shown as 
stick models. The amino acids of the catalytic triad are labeled and drawn as 
white stick models. PPT1’s substrate, palmitate, binds in a hydrophobic 
groove on the surface of PPT1 and is shown here as complexed with Ser115. 
The image was made with DeepView / Swiss PdbViewer 3.7 (SP5) and 
rendered with POV-Ray. 
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PPT1 also separated into two fractions later in the purification from bovine brain 
cytosol by Camp and co-workers. During the last step of purification with 
hydroxyapatite chromatography and increasing NaCl concentration, the enzyme 
activity was separated into two fractions. The first showed PPT1 with several other 
minor bands that did not correlate with enzyme activity, and the second as a 
homogenous band. The separation of the enzyme into two forms could not be 
explained, but protein phosphorylation was thought to be a possible reason for it.  
A more recent proteomic study utilizing post-mortem human brain mannose 6-
phophorylated samples showed as many as 32 different isoforms for PPT1 in 2-D 
gel analyses (Sleat et al. 2005). Each glycosylation form was separated into 
approximately 9 isoforms with different pI. Changes in the isoelectric point of a 
protein occur when the net charge of a protein is changed, for example after amino 
acid substitution, substrate binding or other interactions, or after post-translational 
modifications. 
F u n c t i o n  
PPT1 was originally characterized as a classic soluble lysosomal enzyme 
participating in the catabolism of S-acylated proteins. In human lymphoblasts, PPT1 
removes thioester-linked fatty acids from cysteine-residues in proteins (Lu et al. 
1996). The in vivo substrates of PPT1 are not known, but in vitro experiments have 
shown PPT1 to be able to remove palmitate and other fatty acids from peptides and 
proteins such as GAP-43 (growth-associated protein) and rhodopsin (Cho et al. 
2000b). The pH scale for PPT1 activity is broad, the optimum being at 6.5 to 7.0. It 
is unusually high for a lysosomal enzyme and suggests functionality also outside of 
lysosomes. 
PPT1 has a homolog, PPT2, which shares 26% identity with PPT1. The crystal 
structures of the two proteins are very similar (Calero et al. 2003) but their substrate 
specificity varies: PPT1 has a more restricted range of fatty acyl chain lengths 
(optimum at 14 to 18) whereas PPT2 also has thioesterase activity against lipids 
with less than 10 and more than 18 carbons. While PPT1 is able to depalmitoylate 
proteins, PPT2 cannot bind to fatty acids with bulky head groups. PPT2 is not 
known to be mutated in humans, but the Ppt2-deficient mouse model develops an 
NCL-like phenotype with neurovisceral features (Gupta et al. 2003). 
L o c a l i z a t i o n  
PPT1 is expressed abundantly in most tissues. In the mouse brain, the expression of 
PPT1 starts as early as the eighth embryonic day and it is developmentally regulated 
in the rat and mouse brain (Isosomppi et al. 1999, Suopanki et al. 1999a). This is 
also the case in humans, as PPT1 expression was shown to increase during 
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corticogenesis in the human embryonic brain by in situ hybridization and 
immunohistochemistry (Heinonen et al. 2000b). Studies on neuron cultures showed 
that PPT1 expression increases during neuron maturation and precedes the 
expression of synaptic markers (Ahtiainen et al. 2003). 
In non-neuronal cells, PPT1 is lysosomally targeted and utilizes the mannose 6-
phosphate receptor-mediated pathway (Hellsten et al. 1996, Verkruyse and Hofmann 
1996, Verkruyse et al. 1997). In murine primary neuron cultures, SFV-mediated 
PPT1 showed colocalization with synaptic vesicle protein SV2 while no visible 
colocalization with lysosomal LAMP1 was detected in immunofluorescence studies. 
Endogenous PPT1 showed similar distribution in mouse brain fractionation studies 
(Lehtovirta et al. 2001). This finding has been replicated by immunofluorescence 
studies with endogenous PPT1 (Ahtiainen et al. 2003, Suopanki et al. 2002), 
although negative findings also exist (Virmani et al. 2005). After excitotoxicity 
induced by kainic acid in adult rats, the expression of PPT1 was increased and its 
colocalization with the synaptic membrane marker NMDAR2B was enhanced, 
suggesting a role for PPT1 in synaptic plasticity (Suopanki et al. 2002). 
2.4.10 PPT1 and membrane lipids 
The phospholipid content of post-mortem brain samples of INCL patients has been 
analyzed with chromatography and mass spectrometric methods (Kakela et al. 
2003). Over 60% of the normal phospholipid content was lost due to neuron loss and 
demyelination, and the remaining proportions of phospholipids were altered with an 
increase in phosphatidylcholine and decrease in phosphatidylserine and 
phosphatidylethanolamine levels. Lysobisphosphatic acid (LBPA or BMP) content 
was nearly 100 times higher in the INCL brain than in controls and LBPA was 
found to be rich in polyunsaturated fatty acids. The authors discussed that high 
LBPA content could be derived from increased autophagocytosis and lysosomal 
proliferation. However, as seen in CLN8 patients (Hermansson et al. 2005), the 
brain lipid content varies greatly when the disease progresses and further studies are 
needed to detect early changes in brain lipids. The complex architecture of the brain 
may also contribute to variable findings, since the lipid content varies between 
different brain regions. 
In another study, the overexpression of PPT1 led to a decrease in the ceramide 
content of lipid rafts while it was increased by the overexpression of neutral 
sphingomyelinase (Goswami et al. 2005). The results are in line with the function of 
the proteins; sphingomyelinases catalyse the degradation of sphingomyelin to 
ceramide and phosphocholine, and PPT1 deficiency leads to abnormal processing of 
saposin D, which is involved in ceramide degradation. Interestingly, a fraction of the 
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overexpressed proteins was also shown to localize to rafts, suggesting a possible 
function for PPT1 in the plasma membrane. 
2.4.11 Simple experimental models for INCL 
An efficient way to study the human disease pathogenesis is provided by simple 
experimental disease models, such as yeast, the fruit fly, and a nematode worm. The 
CLN1 gene is conserved in eukaryotes, making the development of INCL disease 
models possible. While in budding yeast (S. cerevisiae) PPT1 does not have an 
ortholog, in fission yeast (S. pombe) such a gene exists, possessing 31% identity 
with the human PPT1. The Ppt1-encoding gene is fused in frame with the Dolpp1 
gene (ortholog for DOLPP1, dolichol pyrophosphate phosphatase-1). This fusion 
gene pdf1 encodes the precursor protein Pdf1p, which is cleaved into Ppt1p and 
Dolpp1p. Dolpp1p deficiency is lethal while Ppt1p-deficient cells are viable. 
However, cells containing no functional copy of Ppt1p were abnormally sensitive to 
vanadate and elevated extracellular pH – phenotypes linked to dysfunction in 
vacuolar acidification and vacuolar protein sorting. Vacuoles in yeast are equivalent 
to lysosomes in mammals. Human PPT1 was able to complement these phenotypes, 
suggesting an evolutionarily conserved function for PPT1 (Cho and Hofmann 2004). 
C. elegans, a nematode worm, has a completely mapped cell lineage and nervous 
system and is therefore often used in neurobiological studies. C. elegans has an 
ortholog gene, ppt-1, for the human CLN1, with 54% identity and 75% similarity. 
After ppt-1 knockout mutation, the overall phenotype of the worms was mild, and 
no alterations or defects in life span, body size, or locomotion were detected. 
Storage material also was not detected. Residual PPT1-like activity was detected in 
the knockout worms, suggesting the presence of a compensatory enzyme. The most 
striking finding concerned the myocytic and neuronal mitochondria, which were 
structurally abnormal, showing membrane whorling and abnormal cristae. The 
overall number and total area of mitochondria were also increased. The defect was 
the strongest at the first day of adulthood and decreased during the course of life. 
Thus, the authors suggested that ppt-1/PPT1 could be involved in the regulation or 
biogenesis of this organelle. (Porter et al. 2005) Mitochondrial dysfunction has also 
been linked to NCLs previously (see Chapter 2.4.3). 
Drosophila melanogaster, a fruit fly, has an ortholog of human PPT1 (55% identical 
and 72% similar), but the overall PPT1 activity in the fly, as well as in C. elegans, is 
significantly lower than in mammals (Glaser et al. 2003). Regardless, Ppt1 
deficiency in the fly leads to abnormal storage material accumulation and reduced 
lifespan, although no obvious neurodegeneration is seen (Hickey et al. 2006). The 
overexpression of Ppt1 results in increased apoptosis in the developing visual 
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system (rough eye) (Korey and MacDonald 2003). Drosophila is a model commonly 
used for modifier gene screening, and this procedure was used to elucidate the 
function of Ppt1 as well. Ppt1-overexpressing stock was crossed with nearly 2000 
other genetically modified stocks and the progeny were screened for either enhanced 
or suppressed eye degeneration phenotype (Buff et al. 2007). The screen revealed 
ten enhancer and ten suppressor genes for Ppt1-induced degeneration. Modifier 
genes were involved in endosomal trafficking and lipid metabolism, ubiquination, 
cell adhesion, and signalling pathways. Some of the most interesting enhancers were 
endophilin A and blue cheese (Bchs), involved in synaptic vesicle recycling and 
endo-lysosomal maturation in neurons. Two genes participating in lipid metabolism, 
phosphatidylserine decarboxylase and ATP-binding cassette homolog, were also 
enhancers of Ppt1. Ppt1 suppressors included Hsc70-3, a fly homolog of BiP, an ER-
resident chaperone. Two suppressors involved in synaptic function were 
synaptotagmin and stoned A, an adaptor protein involved in the recycling of 
synaptotagmin. Synaptotagmin is a Ca2+-sensor for synaptic vesicle fusion and 
neurotransmitter release at the active zone. Overall, these findings support the 
suggested connection between INCL and early defects in the function of synapses. 
The results await replication in higher eukaryotic systems, since although the 
exocytic proteins in presynaptic terminals are conserved between insects and the 
human, the same is not true for the endocytic proteins (Yanay et al. 2008). Thus the 
synapse maturation in the human is likely to differ from that in the fly. Additionally, 
recent links between lipid metabolism and NCL disorders may not be optimally 
studied in Drosophila due to differences in lipid metabolic routes of mammals and 
Drosophila, as evidenced by the inability of the fly to synthesize cholesterol (Gilbert 
et al. 2002). 
2.4.12 INCL mouse models 
Although the above-mentioned simple experimental models have their own 
advantages for studying human diseases, they do not provide enough information 
about the subtle neurobiological changes and cascades behind NCL disease 
pathogenesis. There are also some obvious limitations in studying the 
neurodegeneration in patients, although for example imaging techniques have 
provided new information about the early events in neuronal dysfunction. In order to 
understand the functional consequences of the disease mutation, and to evaluate 
possible treatments, it is necessary to model the diseases in mammals. 
The mouse (Mus musculus) is the most important disease model in molecular 
medicine for many reasons: the mouse genome is fully sequenced and techniques for 
genetic engineering are refined, mice reproduce fast and are relatively easy to 
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maintain, and most importantly, mice share conserved physiological pathways and a 
similar genome with the human (Mouse Genome Sequencing et al. 2002). Mouse 
Ppt1 protein is 84.6% identical and 96.3% similar to the human PPT1 (Salonen et al. 
1998). For INCL research, two different knock-out mouse models have been 
developed. The Ppt1-/- mouse by Gupta and co-workers is made by inserting a stop 
codon mutation into exon 9 (Gupta et al. 2001), and the Ppt1ex4 mouse by Jalanko 
and co-workers is made by a complete deletion of exon 4 (Jalanko et al. 2005). Both 
models lack Ppt1 enzyme activity and develop an INCL-like phenotype. 
Intracellular storage material (GROD) accumulates and mice display early-onset 
progressive neurodegeneration and a shortened lifespan. Ppt1ex4 mice show loss of 
vision at the age of 2 months, seizures from 4 months onward, paralysis of the hind 
limbs at 5 months, followed by death a few weeks later. Ppt1-deficient mice have 
provided crucial information about INCL disease pathogenesis (discussed in more 
detail below). In addition, they are utilized in biochemical and cell biological 
research and offer the possibility to evaluate the efficacy of treatments before 
proceeding into clinical trials with patients.  
2.4.13 Treatment strategies for INCL 
Three therapeutic trials for the treatment of Ppt1-deficient mice utilizing adeno-
associated virus 2 (AAV2) -mediated PPT1 gene therapy have been reported 
(Griffey et al. 2004, Griffey et al. 2005, Griffey et al. 2006). The idea behind the 
virus-mediated gene therapy in lysosomal disorders is based on the trafficking of 
soluble lysosomal enzymes: when infected cells overproduce the missing lysosomal 
protein, they also secrete it. Neighboring cells are then able to endocytose the 
protein by utilizing the CI-MPR and to thus complement their deficiency. AAV-
mediated gene therapy trials have been successful with many different lysosomal 
enzymes. A trial to treat LINCL (the deficiency of TPP1) showed long-lasting 
correction of enzyme activity and efficient enzyme diffusion throughout the mouse 
brain and positive results were also obtained in nonhuman primates (Hackett et al. 
2005, Passini et al. 2006, Sondhi et al. 2005, Sondhi et al. 2007). Consequently, 
human trials have been initiated to treat LINCL (Crystal et al. 2004). Although Ppt1-
deficient mice also showed some improvement in brain histology and behaviour, 
there was no correspondence in seizure activity or life span. This was due to a 
limited diffusion of the enzyme in the mouse brain, proposing that Ppt1-trafficking 
may not follow the classic route of lysosomal enzymes in neurons. Recent 
publications have described novel routes for lysosomal transport, mediated for 
example by sortilin and LIMP-2 (discussed in Chapter 2.2.3). It will be interesting to 
analyze whether alternative trafficking routes also exist for PPT1. 
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2.4.14 Suggested mechanisms behind neurodegeneration in INCL 
Neurodegeneration in INCL has been proposed to be caused by several underlying 
mechanisms, the increased vulnerability of neurons to apoptosis being one of them. 
Apoptotic mechanisms are involved in INCL as increased apoptosis has been 
detected in the brain biopsies of INCL patients (Riikonen et al. 2000). Studies 
utilizing PPT1 overexpression and inhibition in LA-N-5 neuroblastoma cells have 
suggested PPT1 to act as an anti-apoptotic protein (Cho et al. 2000a, Cho and 
Dawson 2000). Cancer studies support this finding, as increased PPT1 expression is 
seen in colorectal cancer metastasis (Tsukamoto et al. 2006) and inhibition of PPT1 
kills cultured tumor cells (Dawson et al. 2002). A recent large-scale proteomic 
approach revealed an interaction between PPT1 and the c-MYC oncogene, linking 
PPT1 more tightly to cell cycle regulation (Koch et al. 2007, Trumpp et al. 2001). 
However, the function of this interaction was not discussed and its location is 
unknown, as PPT1 is intravesicular and c-MYC resides in the cytosol and nucleus. 
Increased expression of other NCL proteins (CTSD, TPP1 and CLN3) in cancer has 
also been reported (Junaid et al. 2000, Rylova et al. 2002). 
Increased apoptosis in the INCL brain has been proposed to result from ER stress 
leading to the unfolded protein response and apoptosis via activation of caspase-4 
and caspase-3 (Kim et al. 2006b, Zhang et al. 2006). ER stress has also been 
suggested to increase the amount of reactive oxygen species that destabilize the 
mitochondrial membrane and activate caspase-9-mediated apoptosis (Kim et al. 
2006c). However, ER and oxidative stresses were later shown to also be common 
mediators of apoptosis in many other lysosomal storage disorders with or without 
neuronal manifestations, and thus not specific for PPT1 deficiency (Wei et al. 2008). 
Neuronal apoptosis is followed by the removal of the cell corpses by phagocytes 
(activated microglia, astroglia, and macrophages). Growing evidence suggests that 
although microglial activation is crucial to neuron survival and host defence, 
overactivation can lead to increased neurotoxicity and progressive cell death (Block 
et al. 2007). Microgliosis is also evident in the INCL brain. Increased levels of 
lysophosphatidylcholine, a chemoattractant for phagocytes, together with imperfect 
phagocytosis by the Ppt1-deficient phagocytes, were suggested to contribute to 
microgliosis and progressive neuronal death in the Ppt1-deficient mouse brain 
(Zhang et al. 2007). 
The initiating steps in the disease course remained unknown until recent 
histopathological data from sheep and mouse models. Examination of mouse brains 
that model various NCL subtypes has pointed out that certain neuron populations are 
more vulnerable to the effects of the disease than others and that there is a special 
sequence of events that precedes the massive cortical neuronal death (Cooper et al. 
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2006). In the Ppt1-deficient mice, it is the thalamus that shows the first signs of neuron 
loss, together with localized activation of astrocytes and microglia (Kielar et al. 2007). 
The first affected nucleus in the thalamus is the lateral dorsal geniculate nucleus 
(LGNd) within the visual system, followed by the loss of neurons in the auditory and 
somatosensory nuclei. Cortical neuron loss appears only months after the loss of 
thalamic relay neurons (Bible et al. 2004) and is suggested to be the consequence of 
reduced afferent signalling from the thalamus. The affected neuronal populations have 
been identified to some extent and several studies indicate that the inhibitory 
GABAergic interneurons are severely affected in the Ppt1-deficient mice (Jalanko et 
al. 2005) as well as in all NCL mouse models studied (Cooper et al. 2006). 
The reason for thalamocortical neuron loss is still elusive, but astrocytes have been 
suggested to play an important role in the pathogenesis. The distribution of 
astrocytosis predicts the subsequent distribution of neuron loss in many NCL mouse 
models and suggests a possible role for neuron-glia interactions in the course of 
disease (Cooper et al. 2006). Whether the principal glial activation is protective or 
harmful to neurons is not known, but as already mentioned, microglial 
overactivation potentially promotes neuronal death. Astrocytes are important in the 
maintenance of the synapse, and evidence of synaptic defects with a reduced pool of 
synaptic vesicles has been reported in Ppt1-deficient mice (Virmani et al. 2005). 
However, thorough electrophysiological recordings in acute hippocampal slices of 
the 1-month-old Ppt1ex4 mice showed no abnormalities, suggesting normal synaptic 
function in these mice (Ahtiainen et al. 2007). This study further revealed that 
neuronal cholesterol metabolism, also highly interconnected with astrocytes and 
discussed in more detail in Chapter 2.3, show fundamental changes in the Ppt1-
defient neurons (Ahtiainen et al. 2007). Gene expression-profiling studies on 
cultured neurons showed upregulation of cholesterol biosynthesis. Functional 
experiments certified the gene expression data; the rate of sterol biosynthesis and 
conversion of sterol precursors into cholesterol were upregulated, but the amounts of 
intracellular cholesterol and precursors were constant or diminished, respectively. 
Maintenance of the correct lipid composition in neuronal membranes is essential for 
the correct function of the cell and any disruption in it is more than likely to disturb 
neuronal development or aggravate, if not cause, the neuronal death. 
2.4.15 vLINCLFin – clinical findings 
Mutations in the CLN5 gene result in the Finnish variant late infantile NCL (MIM 
256731) (Santavuori et al. 1982), named so because it is enriched and was described 
in Finland, and it is distinctive both clinically and neuropathologically from the 
classic LINCL caused by mutations in the CLN2 gene. The first clinical signs are 
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observed between the ages of 4 to 6 years, first with attention deficits and motor 
clumsiness, followed by learning problems, visual impairment, and mental decline. 
Epileptic seizures, ataxia, and myoclonic jerks are important features of the disease 
and manifest between 7 to 10 years of age. Magnetic resonance imaging shows early 
cerebellar atrophy, and T2-weighted images show decreased signal intensity of the 
thalami (Autti et al. 1992). Progressive optic atrophy and macular dystrophy lead to 
blindness before the age of ten, and patients survive until 14 to 32 years of age 
(Santavuori et al. 2000). 
2.4.16 Neuropathology of vLINCLFin 
Neuropathologically vLINCLFin is characterized by severe cerebral and extreme 
cerebellar atrophy. The cerebellar Purkinje and granular cells are almost totally 
obliterated, while most subcortical structures show relatively modest neuronal loss. 
The cerebral neuron loss is particularly evident in layers III and V, and there is 
severe cortical astrocytosis and loss of myelin in the white matter. The ultrastructure 
of the intraneuronal storage bodies possesses both rectilinear complexes and 
curvilinear profiles (Figure 8). Some cells also show fingerprint patterns. The main 
storage protein component is subunit c of ATP synthase, and minor amounts of 
SAPs A and D can also be detected (Tyynela et al. 1997). 
2.4.17 CLN5 gene and mutations 
The CLN5 gene, identified in 1998, is located on chromosome 13q22 and has four 
exons. It is expressed widely in different tissues (Savukoski et al. 1998). The CLN5 
gene is conserved only in vertebrates (Siintola et al. 2006). Immunohistochemical 
studies, together with in situ hybridization, showed that the expression of CLN5 in 
the human brain begins at the early developmental stage and increases during 
corticogenesis (Heinonen et al. 2000b). Expression analyses in the mouse showed 
similar results of increasing expression during brain development. In the adult 
mouse brain, Cln5 expression is most intense in the cerebellar Purkinje cells, 
cerebral cortex, and the principal cell layers of the hippocampus (Holmberg et al. 
2004). This is well in line with the neuropathological findings in humans. Over 90% 
of the Finnish CLN5 patients carry the major mutation (CLN5FinMajor, c.1175delAT, 
Y392X), which is predicted to lead to a 16-aa truncation of the CLN5 polypeptide 
(Savukoski et al. 1998). To date, mutations in all four exons have also been found  
in families from other European countries and Latin America, and the present 
number of reported mutations in the CLN5 gene is 13 (NCL resource database, 
http://www.ucl.ac.uk/ncl/cln5.shtml). 
 52 
 
Figure 8. Lysosomal storage material in a vLINCLFin patient’s tissue forms 
curvilinear profiles. Figure courtesy of Prof. Juhani Rapola. 
2.4.18 The CLN5 protein 
The CLN5 protein shows no homology to other known proteins and its function is still 
unknown. The human CLN5 coding sequence contains four possible ATG initiation 
sites, and it was initially suggested that the most 5’ upstream site was the functional 
one, producing a 407-aa polypeptide with two transmembrane domains. However, 
subsequent protein expression studies revealed expression of a highly glycosylated 
protein migrating as a 60-kDa band. After deglycosylation with PNGase F, the size 
decreased down to 38 kDa, smaller than the theoretical size of a polypeptide translated 
from the first methionine. These results together with an alignment with the mouse 
Cln5 gene suggest that the fourth methionine is the major initiation site, leading to an 
expression of a soluble lysosomal glycoprotein.  Lysosomal trafficking was shown to 
be blocked when the CLN5 polypeptide carried the major Finnish mutation (Holmberg 
et al. 2004, Isosomppi et al. 2002). Supporting evidence for the solubility and 
lysosomal localization has been derived from proteomic studies where CLN5 has been 
found to possess a classic lysosomal mannose 6-phosphate targeting motif (Sleat et al. 
2005, Sleat et al. 2007). Only one ATG initiation site is present in the CLN5 gene in 
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mice, dogs, cattle, and sheep, and recent alignments with the human sequence suggest 
that it is the third, rather than the fourth, human initiation site that is evolutionary 
conserved (Frugier et al. 2008). This start codon would result in a soluble protein of 
358 amino acids. It has been suggested that the unusually long 5’ UTR region in the 
originally reported human CLN5 gene could actually represent the pre-mRNA form of 
CLN5, containing the 5’ end intron which could participate in the regulation of tissue-
specific CLN5 gene expression (Isosomppi 2003). This type of regulation has been 
demonstrated to occur for example in the RNA-editing ADAR enzymes (Lykke-
Andersen et al. 2007). In the future, it would be very interesting to characterize the 
human CLN5 protein in more detail and to investigate the role of the four possible 
initiation sites in the expression of CLN5 in different tissues in order to better 
understand its function. 
2.4.19 Animal models for vLINCLFin 
A Cln5-deficient mouse model has been developed by a targeted deletion of exon 3 
of the mouse Cln5 gene (Kopra et al. 2004). The mouse model shows the 
accumulation of autofluorescent material and loss of vision, but no significant brain 
atrophy. Downregulation of genes coding for the myelin components was detected, 
mirroring the loss of myelin detected in the vLINCLFin patients. Loss of GABAergic 
interneurons was detected in several brain areas. Naturally occurring mutations have 
recently been found also in the canine, bovine, and ovine CLN5 genes (Frugier et al. 
2008, Houweling et al. 2006, Melville et al. 2005a). Ovine CLN5 in Borderdale 
sheep resembles the human disease with respect to the clinical and pathological 
courses. One of the first symptoms in affected sheep is blindness, accompanied by a 
tendency to walk in circles (Jolly et al. 2002a). Their gyrencephalic brains, together 
with their size and human-like physiology, make sheep a valuable model for future 
therapeutic interventions. 
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3 AIMS OF THE STUDY 
Prior to this study, PPT1 had been suggested to have a distinct extralysosomal role 
in neurons. The function of CLN5 was totally elusive. This study was initiated to 
describe protein interaction partners for PPT1 and CLN5 in order to elucidate their 
function in vivo and the cellular mechanisms involved in the pathogenesis of INCL 
and vLINCLFin. The aims addressed in this study were the following: 
 
• To study the differences in PPT1 processing in neurons and non-neuronal 
cells, and to compare the trafficking of PPT1 to the classic lysosomal 
enzyme AGA 
 
• To find interaction partners for PPT1 and CLN5 
 
• To study the effects of these interactions on the localization and/or 
processing of the interaction partners in wild type and in PPT1- and CLN5-
deficient cells 
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4 MATERIALS AND METHODS 
The materials and methods used in this study are described in the original 
publications. 
 
Table 2. Materials and methods used in this study 
Material or Method Original publication 
Adenovirus -mediated gene expression I, II 
Antibody internalization assay I 
Antibody production and purification I 
Apolipoprotein A-I internalization assay II 
Assay for PPT1 activity I 
Cell fractionation I 
Cell surface biotinylation II 
Cloning of cDNAs and other plasmid constructs I, II, III 
Confocal microscopy I, II, III 
Glycosylation analyses I 
Dissection and culturing of primary neurons and glial cells I, II 
DNA extraction I, II, III 
Immunohistochemistry II, III 
Immunoprecipitation I 
In vitro- binding assays with GFP- and GST-fusion proteins I, II, III 
Lipid analysis from mouse serum II 
Metabolic labeling I 
Mouse brain tissue preparation II 
Primary fibroblast cultures II 
Prevention of palmitoylation with 2-bromopalmitate II 
Protein detection by direct and indirect immunofluorescence I, II, III 
Protein detection by silver staining II 
Protein detection by Western analysis I, II, III 
Protein identification by mass spectrometry II 
Protein production in stabile CHO-cells I 
Protein production in E.coli  I, II, III 
Protein purification by chromatographic methods II 
Quantification of immunofluorescence images II 
Semliki Forest virus –mediated gene expression I 
Surface plasmon resonance analysis (Biacore) I, II 
TIRF microscopy II 
Transient transfections I, III 
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5 RESULTS AND DISCUSSION 
5.1 Evidence of a neuron-specific pattern for PPT1 (I) 
Preceding this study, the intracellular localization of PPT1 was shown to be 
lysosomal in non-neuronal cells (Hellsten et al. 1996, Verkruyse and Hofmann 
1996). In neurons, however, the endogenous and overexpressed PPT1 was enriched 
in synaptosomes and synaptic vesicles rather than in lysosomes (Lehtovirta et al. 
2001). Later it was demonstrated that PPT1 colocalizes with presynaptic markers in 
the axonal varicosities and that its activity increases during neuronal maturation 
(Ahtiainen et al. 2003). The expression of PPT1 in the CNS had also been shown to 
be developmentally regulated and to be concurrent with or slightly preceding 
synaptogenesis (Heinonen et al. 2000a, Isosomppi et al. 1999, Suopanki et al. 
1999b). Since the most prominent result of PPT1 deficiency in INCL patients is the 
massive neuronal death and previous studies had suggested an extralysosomal 
function for PPT1 in neurons, it was meaningful to compare PPT1 expressed in 
neurons and in non-neuronal cells in order to reveal any differences in its 
processing. It was also of interest to compare the intracellular trafficking of PPT1 
with another well characterized lysosomal enzyme to reveal possible differences in 
their localization.  
5.1.1 PPT1 is differentially modified in neurons vs. non-neuronal cells 
The comparison of neuronal and non-neuronal PPT1 was approached by 
overexpressing adenovirus-mediated PPT1 in mouse primary fibroblasts and 
neurons. Western blot analysis revealed a difference in the glycosylation pattern of 
PPT1 between the two cell types, and also an apparent difference in the migration of 
the glycosylated forms. To deglycosylate the proteins, samples were treated with 
PNGaseF, an amidase that cleaves between the innermost GlcNAc and asparagine 
residues, removing the N-linked oligosaccharides from the polypeptide chain. After 
the treatment, PPT1 separated into two bands in fibroblasts while only one band was 
detected in neurons. This neuronal band migrated in between the two bands from 
fibroblasts (I, Figure 3). The specific nature of this difference is unknown, but 
because the same cDNA was used to express PPT1 in both cell types, it is likely that 
the shift is due to difference in the post-translational modifications (PTM). So far, 
N-glycosylation is the only PTM described in PPT1. It is possible that in different 
cells, PPT1 is proteolytically differently trimmed, which could explain the small 
shift in size between fibroblast and neuronal PPT1. The two PPT1 bands in 
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fibroblasts after deglycosylation represent two forms of PPT1, of which only one is 
seen in neurons. Database searches suggest phosphorylation and S-palmitoylation as 
possible modifications for PPT1, while prenylation, sulfination, myristoylation, and 
GPI-anchoring are unlikely. Phosphorylation increases the negative charge of the 
protein, but it also increases its mass. Therefore, it could cause the protein to migrate 
differently in the gel, or does not necessarily affect the mobility of a protein at all. 
The samples were boiled and treated with -mercaptoethanol to reduce protein 
disulfide bonds. This treatment has been reported to also reduce the thioester bonds 
in a concentration-dependent manner (Hausmann et al. 1998, Schmidt et al. 1988). 
In our experiment, the concentration of -mercaptoethanol was 1.4 M, and similar 
concentrations have been reported to reduce 90% of S-palmitoylation. However, this 
aspect was not specifically studied here, and it thus remains for further studies to 
examine the nature of the modification. This experiment is the first to show 
structural differences in PPT1 between neurons and non-neuronal cells, and supports 
the previous evidence for the neuron-specific function of PPT1. One example of a 
protein with neuron-specific processing is cholecystokinin, a hormone released from 
the gut but also from cerebral and peripheral neurons (Rehfeld et al. 2003). Different 
prohormone convertases act on procholecystokinin in different tissues, but 
differences in the cell cycle and granule maturation also affect the deviating 
cholecystokinin patterns in the CNS and gut. This may also be true for PPT1 – 
membrane maturation and trafficking are likely to be different in fibroblasts and 
neurons, but cell-specific enzymes modifying PPT1 are possible as well. 
5.1.2 Transport of PPT1 differs from that of the classic lysosomal 
enzyme AGA 
PPT1 has been shown to undergo mannose 6-phosphorylation in non-neuronal cells 
(Hellsten et al. 1996, Verkruyse and Hofmann 1996). In neurons, this modification 
has not been studied. Gene therapy trials suggest that the transport of PPT1 in the 
CNS is different from traditional lysosomal enzymes such as 
aspartylglucosaminidase (AGA). The virus-mediated PPT1 enzyme does not diffuse 
as effectively in the mouse brain as AGA and other mannose 6-phophorylated 
enzymes (Griffey et al. 2006, Sondhi et al. 2005, Virta et al. 2006). Furthermore, our 
initial experiments suggested a very inefficient uptake of PPT1 from conditioned 
media into different cell cultures (data not shown). We compared the trafficking of 
PPT1 and AGA in mouse fibroblasts and neurons by overexpressing the adenovirus-
mediated proteins and detecting them with specific antibodies using an antibody 
internalization assay rather than the traditional immunodetection, where antibody 
labelling is done after fixation of the cells. This method allowed us to detect PPT1 
and AGA recycled back to the interior of the cell from the plasma membrane. Only a 
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small fraction of PPT1 was detected in LAMP-1 positive vesicles in fibroblasts (I, 
Figure 3C), whereas most of the AGA colocalized with lysosomal LAMP-1 (data 
not shown). Also, PPT1 positive vesicles were close to the plasma membrane and 
cell projections in neurons, distinctive from the perinuclear distribution of AGA.  
These data, together with the above data about the possible different neuronal 
modifications of PPT1, strengthen the hypothesis of PPT1 utilizing another 
trafficking route in addition to the MPR-regulated pathway that is used by AGA and 
the majority of soluble lysosomal enzymes. Due to the severity of the INCL disease, 
PPT1 was originally anticipated to be indispensable to very basic neuronal 
functions, such as synaptic transmission or recovery from excitotoxic events. 
However, studies conducted by Ahtiainen and co-workers revealed an improved 
recovery of Ppt1-deficient neurons after glutamate-induced stress, and no effects on 
their electrophysiological properties (Ahtiainen et al. 2007). Compensatory 
mechanisms may play a role in this, as another study showed a progressively 
reduced number of synaptic vesicles (SVs) in the readily releasable pool in Ppt1-
deficient neurons, but again no alterations in the active electrophysiological 
properties (Virmani et al. 2005). Based on the cellular localization, the vesicle pool 
of endocytosed PPT1 demonstrated here could represent early/recycling endosomes. 
Keeping in mind the reported SV localization of PPT1 in neurons, it has been 
speculated that the biogenesis of SVs could start via two overlapping routes: from 
the plasma membrane in an AP2-dependent pathway, and from endosomes in an 
AP3-dependent pathway (Bonanomi et al. 2006). In the future, it would be 
interesting to examine the trafficking of PPT1 in neurons mimicking I-cell disease to 
specify the importance of mannose 6-phosphorylation to its neuronal trafficking. 
Examining the role of the two adaptor proteins in the formation of SVs in the 
absence of PPT1, as well as their role in the localization of PPT1 to SVs, would be 
informative. The possible participation of PPT1 in other trafficking routes described 
for lysosomal proteins, especially those involving sortilin, could in part explain the 
unsatisfactory results from the gene therapy trials.  
5.2 Protein interactions of PPT1 (I- II) 
5.2.1 PPT1 activity resides in a high molecular weight complex (I) 
In order to understand the putative diverse functions of PPT1 in vivo, it was of 
greatest interest to us to examine its interaction partners. As discussed in Chapter 
2.4.9, brain-derived PPT1 has been observed separating into various types of 
fractions during previous purification procedures (Camp and Hofmann 1993). Thus, 
we initiated our analyses by investigating whether PPT1 resides in a monomeric 
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form intracellularly. We utilized the lysosome-containing fraction of the PC12 cells 
and separated the proteins according to their size by size-exclusion chromatography. 
We then analyzed the enzyme activities of endogenous PPT1 and AGA in these 
fractions. The lysosome-containing fraction (10 000 g pellet) also contains 
mitochondria and other dense membrane fractions. AGA activity eluted in three 
sequential fractions correlating to its native homodimeric size, whereas PPT1 
activity was eluted in two major peaks, the first representing a molecular weight of 
over 100 kDa, and the second peak of approximately 40 kDa (I, Figure 4). The latter 
is likely to represent the monomeric PPT1, but the first suggests that the majority of 
PPT1 activity resides in a larger protein complex. Further analyses using a GFP-
PPT1 pull down assay suggested that PPT1 forms complexes where it interacts with 
itself either directly or through other molecules (I, Figure 5A). The nature of the 
complex was not analyzed in this study, but in the following analyses a protein 
complex interacting with PPT1 was identified. 
5.2.2 PPT1 interacts with F1-ATP synthase (I, II) 
To obtain PPT1 for antibody production and protein interaction experiments, we 
utilized stable CHO cells producing PPT1, and purified PPT1 from the medium with 
hydrophobic interaction and size-exclusion chromatographic methods. A 50-kDa 
protein repeatedly co-purified with PPT1. As co-secretion may be a sign of true 
interaction, we proceeded to attempt to identify this protein. After SDS-PAGE and 
Coomassie staining, the band was subjected to mass spectrometric analysis. The 
protein turned out to be the -subunit of mitochondrial F1-ATP synthase (II, 
Supplementary material). This finding was interesting due to the link to subunit c of 
the mitochondrial ATP synthase found in other NCLs. However, at the same time it 
was also inconsistent with the reported localizations of these two proteins. To 
analyze whether a true interaction existed between PPT1 and the -subunit, we 
utilized purified proteins and performed the surface plasmon resonance assay. The 
result was negative between PPT1 and the -subunit. However, when the whole F1-
complex was utilized, a weak but clear concentration-dependent interaction between 
PPT1 and the F1-complex was detected (II, Figure 1). We further tested the 
interaction using the GST-PPT1 pull down assay, and both - and -subunits of the 
F1-complex showed interaction with PPT1 (II, Figure 2). Originally, no other F1-
subunits except  were identified as purifying with PPT1. It is possible that the 
interaction indeed occurs between the -subunit and PPT1, but that the correct 
conformation of the -subunit is required. In the F1-complex, three -subunits and 
three -subunits form the catalytic unit and the ADP/ATP-binding sites are located 
in the -subunits. What could be the reason for the interaction between the F1-
complex and PPT1? Although Fo/F1-subunits are not reported to be palmitoylated, 
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the palmitoylation site prediction program CSS-Palm (Zhou et al. 2006) predicts the 
following putative palmitoylation sites in them: Fo-subunit S – two sites in the 
mitochondrial import sequence and one in the mature protein; Fo-subunit C – one 
site in the mitochondrial import sequence; F1-subunit gamma – one site in the 
mature protein. These sites could be targets for the depalmitoylation function of 
PPT1, and could have the potential to affect the targeting, assembly, degradation, or 
function of the ATP synthase subunits in PPT1-deficient cells. These aspects were 
analyzed next. 
5.2.3 Mitochondrial function is unaltered in Ppt1ex4 mouse brain (II) 
Besides the subunit c accumulation, functional mitochondrial abnormalities have 
also been reported in NCL patients, including INCL patients, as well as animal 
models (discussed in Chapter 2.4.3). We wanted to examine the function of 
mitochondria in the brain of Ppt1-deficient mice in the light of our newly found 
interaction. For this purpose, we extracted the mitochondria from the cerebrum and 
cerebellum of two two-month-old wild type and Ppt1ex4 mice, and examined by 
blue native electrophoresis whether the assembly of mitochondrial complexes was 
affected. The assembly of different respiratory complexes appeared normal after 
Coomassie staining (data not shown). To examine the amounts of nuclearly and 
mitochondrially encoded proteins, we compared the relative amounts of complex II 
(succinate – coenzyme Q reductase) and complex V (ATP synthase). Complex II is 
exclusively encoded by the nuclear DNA, while other respiratory complexes also 
contain mitochondrially encoded subunits (Zeviani and Di Donato 2004). No 
differences were found in their relative amounts compared to the wild type (II, 
Figure 3A). Furthermore, we tested the oxygen consumption of freshly isolated 
mitochondria from Ppt1ex4 mouse brain, and detected no alterations compared to the 
wild type (II, Figure 3B). Even though mitocondria have been suggested to play a 
role in NCL neurodegeneration, our analyses on the mouse brain did not reveal any 
major failure in the assembly or function of ATP synthase or other respiratory 
complexes. It is possible that the alterations in mitochondrial function are subtle and 
may not cause abnormalities in complex assembly or function, at least when 
analyzed at the level of the whole brain tissue. As an example, defects in complex I 
in Parkinson’s disease are demonstrated specifically in the substantia nigra of the 
human brain (Muqit et al. 2006, Schapira 2002). Therefore, in order to investigate 
the role of mitochondria in the neurodegeneration of INCL, temporal and spatial 
analyses of mitochondria in different brain areas, especially in the thalamus, should 
be conducted. At this point, we continued to examine other possibilities for the 
interaction between PPT1 and the F1-complex in order to identify its significance. 
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5.2.4 Increased amount of ectopic F1-ATP synthase in Ppt1ex4 mouse 
neurons (II) 
In addition to mitochondria, F1-subunits have been found on the surface of different 
cell types. Studies reporting ectopic F1-subunits include data from adipocytes, 
hepatocytes, and endothelial cells (Kim et al. 2004, Martinez et al. 2003, Moser et 
al. 2001). Additionally, different proteomic studies have reported F1-subunits in 
lipid rafts extracted from the plasma membrane of various organs, including the 
brain (Bae et al. 2004, Kim et al. 2006a). However, no reports are available 
describing neuronal ectopic F1-subunits. We utilized cell surface biotinylation and 
TIRF micrscopy to investigate the cell surface localization of F1-subunits in mouse 
fibroblasts and neurons. F1-subunits  and  were detected on the surface of both 
cell types, and for the first time on the surface of neurons (II, Figure 5). Western blot 
and immunofluorescence analyses showed that the overall amount of these proteins 
was similar in wild type and Ppt1ex4 mouse cells. When the ectopic amounts of F1-
subunits were compared with TIRF microscopy, an increase in Ppt1ex4 neurons was 
detected (II, Figure 6). However, no difference was detected between the mutant and 
control fibroblasts. 
To examine the functional link between the increase in ectopic F1-subunits and the 
depalmitoylating activity of PPT1, we treated the wild type cells with 2-
bromopalmitate (2BP) to inhibit palmitoylation. Our first hypothesis was that if the 
increase was due to decreased depalmitoylation of proteins by PPT1, then the 
inhibition of palmitoylation would further decrease the amount of ectopic F1. 
However, no decrease in the wild type cells could be seen after overnight treatment 
with 10-100 μM 2BP (II, Figure 6). Palmitoylation can be either a constitutive or 
regulated modification, and the 2BP-procedure has been utilized in examining the 
regulated palmitoylation of cytosolic proteins PSD-95 (post-synaptic density protein 
95) and Fyn (Src family kinase) (El-Husseini Ael et al. 2002, Webb et al. 2000). F1-
subunits are normally membrane-associated through an association with the 
membrane-embedded F0-complex. It is not known whether the whole F1-Fo-complex 
is present at the neuronal plasma membrane, or if only the F1-complex or even the 
individual F1-subunits possess their own ectopic functions. Also unknown is how 
they might be in contact with the membrane. In the light of the reported association 
of the F1-subunits with lipid rafts, one explanation for the increased cell surface 
localization could be the reported defects in receptor-mediated endocytosis in Ppt1-
deficient cells (Ahtiainen et al. 2006). Additionally, defects in saposin trafficking 
and cholesterol metabolism could cause general alterations in the membrane 
composition and influence, for example, the number of lipid rafts in Ppt1-deficient 
cells (Ahtiainen et al. 2007). 
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The function of the ectopic F1-subunits has been studied in hepatocytes, adipocytes, 
and endothelial cells. Depending on the cell type, they can either hydrolyze or 
synthesize ATP. In adipocytes, the amount of F1-subunits was increased during 
adipogenesis and they participated in extracellular ATP synthesis (Kim et al. 2004). 
Ectopic F1-subunits also synthesized ATP in endotelial cells (Moser et al. 2001), while 
in hepatocytes they hydrolysed ATP and the resulting ADP was shown to activate the 
P2Y13 receptor and trigger HDL endocytosis (Jacquet et al. 2005, Martinez et al. 
2003). Many molecules have been shown to act as ligands for F1-subunits 
(Champagne et al. 2006). For example, the -subunit has been identified as a receptor 
for apoA-I, -casomorphin, enterostatin, angiostatin, and circulating factor 6 (CF6). 
Endothelial monocyte activating polypeptide II (EMAP II) was identified as a ligand 
for the -subunit. Ectopic F1-subunits are thus implicated in various processes, such as 
lipid metabolism, angiogenesis, blood pressure regulation, and tumor recognition by 
innate immune cells. Their function in neurons is not known. However, previous 
studies from our group addressed the dysregulation of cholesterol metabolism in 
Ppt1ex4 mouse neurons (Ahtiainen et al. 2007). 
Neuroinflammation is the hallmark of INCL, suggesting a disruption of astrocyte-
neuron crosstalk. Astrocyte-neuron interactions are also essential for neuronal 
cholesterol trafficking and therefore, in order to analyze the function of ectopic F1-
subunits in neurons and astrocytes, we decided to measure the uptake of lipid-poor 
apoA-I. This protocol was chosen as the -subunit had been identified as the 
receptor for apoA-I in hepatocytes, and apoA-I is one of the apolipoproteins present 
in cerebrospinal fluid (CSF). Ppt1-deficient cells were incubated with an excess of 
radiolabelled apoA-I, and the amount of internalized apoA-I was compared to wild 
type cells. The overall uptake was low, but a significant increase in the amount of 
internalized apoA-I was detected in Ppt1-deficient neurons and glial cells (140% and 
118% of wild type, respectively) (II, Figure 7). This result suggested a possible 
connection between the elevated levels of -subunit on the cell surface and the 
increased uptake of apoA-I. Further studies are needed to elucidate the precise 
function of the ectopic F1-subunits in neurons in order to clarify their role in 
ATP/ADP metabolism. P2Y and P2X receptors (or P2 purinoceptors), activated by 
ADP, ATP, and other nucleotides, have recently been linked to many different 
functions in the CNS. One of them is CNS development (Zimmermann 2006). The 
proliferative capacity of Ppt1-deficient progenitor cells has been reported to be 
enhanced (Ahtiainen et al. 2007). Because purinergic signalling has been reported to 
sustain and enhance the proliferation of neural progenitor cells (Lin et al. 2007), 
there may be a link between the two. Purinoceptors seem especially important to 
glial cells in intercellular communication, and misregulation of these receptors has 
been implicated in diverse pathological conditions, including microglial activation 
after neuronal injury and disease-linked neurodegeneration (Franke and Illes 2006, 
 63 
Inoue et al. 2007). Altered nucleotide signaling might thus play a role in INCL 
pathogenesis as well. 
5.2.5 Evidence of dysfunction in cellular and systemic lipid metabolism 
in Ppt1ex4 mice 
Next, it would have been of significant interest to us to compare the lipoprotein 
levels in the CSF of Ppt1ex4 and wild type mice. Alterations in CSF lipoprotein 
levels have been reported in patients with neurodegenerative diseases (Michikawa 
2004, Vuletic et al. 2005). However, sufficient CSF samples are very difficult to 
obtain from mice because of their small size. Therefore, we decided to compare 
various serum lipid parameters between the wild type and Ppt1-deficient mice, since 
in addition of being present in the CSF, apoA-I is the major apolipoprotein in 
plasma HDL. The amounts of cholesterol, triglycerides, apoA-I, and apoE, as well 
as the activity of plasma phospholipid transfer protein (PLTP), were investigated in 
1-month-old mice. Interestingly, cholesterol, PLTP, and apoA-I levels were 
significantly reduced in Ppt1-deficient mice (II, Figure 8). PLTP transfers 
phospholipid-rich surface remnants from hydrolyzed triglyceride-rich lipoprotein 
particles to HDL, modulating its size and composition (Qin et al. 2000). No 
differences in the apoE serum levels were detected. However, a significant decrease 
in the particle size of apoE-rich HDL lipoproteins was detected. Disturbances in the 
function of apoE have been studied in the apoE-deficient mouse model. These mice 
develop atherosclerosis and signs of neuronal deficits, mirroring the results of apoE 
dysfunction in humans (Moghadasian et al. 2001, Veinbergs et al. 1998). 
Reduced adiposity, cholesterol levels, and triglycerides were recently reported in the 
INCL mouse model as well as in several other mouse models of lysosomal storage 
diseases (Woloszynek et al. 2007). Lysosomal storage per se was hypothesized to 
cause energy depletion, because cells lack the nutritients recycled by lysosomes, 
and, in addition, they have to “maintain” the storage. The reduced cholesterol and 
lipoprotein levels we detected may well reflect the alterations in the energy balance. 
The only human study reporting abnormal lipoprotein profiles in NCLs was done 
with JNCL patients and dates back to the 1980’s (Bennett et al. 1986). Bennett and 
co-workers found decreased levels of the VLDL fraction in patients’ sera. Since 
VLDL is the major lipoprotein carrier for triglycerides, their results could also 
reflect reduced adiposity and energy depletion due to lysosomal storage. The 
reduction in particle size of the apoE-containing HDL lipoproteins has not been 
linked to energy balance, but may reflect a disturbance in the maturation and 
subclass distribution of HDL and has been connected to the apoE4 genotype in 
human studies (Dart and Cooper 1999, Topic et al. 2008). 
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5.3 Interaction of PPT1 with CLN5 (III) 
5.3.1 Interactions of CLN5 with five other NCL proteins 
NCL diseases resemble each other both clinically and histopathologically. However, 
eight different genes have already been identified behind these diseases, and it has 
been estimated that at least two more genes wait to be identified (Siintola et al. 
2006). Therefore, it is tempting to hypothesize that NCL proteins could be 
functionally connected and participate in one common pathway at different levels. It 
was previously known from the GST-pull down experiments that CLN5 interacts 
with two other NCL proteins, CLN2/TPP1 and CLN3 (Vesa et al. 2002). One study 
also described that NCL proteins could complement each other and correct growth 
and apoptotic defects in mouse fibroblasts (Persaud-Sawin et al. 2007). To elucidate 
the possible functional connections between different NCL proteins, we utilized the 
GST-CLN5 pull down assay to fish endogenous NCL proteins from mouse brain 
extract and HeLa lysate. GST-vector and other lysosomal/ER proteins were used as 
controls. We were able to replicate the interactions between CLN5 and CLN2/TPP1 
and CLN3 (III, Figure 1). In addition, we detected three novel interactions between 
CLN5 and other NCL proteins when PPT1, CLN6, and CLN8 precipitated with 
CLN5. We could not detect the endogenous CLN8 to bind to CLN5, but when 
CLN8 possessing a HA-tag was overexpressed in COS-1 cells, an interaction was 
observed. LAMP-1 and cathepsin D were negative for CLN5 interaction. To 
conclude, CLN5, a soluble lysosomal protein, showed interactions with two other 
soluble lysosomal enzymes, PPT1 and TPP1, one endo/lysosomal transmembrane 
protein, CLN3, as well as with two ER transmembrane proteins, CLN6 and CLN8. 
The detected interactions between the ER-resident and lysosomal proteins could be 
explained by the possible actions of the ER-proteins on CLN5, as the post-
translational modifications or folding of CLN5 could be modified by CLN6/CLN8. 
Another possibility is that CLN5 already has a function in the ER, and CLN6 and 
CLN8, and possibly other interaction partners as well, are the objects of this 
function. In either case, the hypothesis of a common pathway affected in NCLs is 
supported by the multiple interactions of CLN5 with other NCL proteins. 
5.3.2 Effects of the PPT1 – CLN5 interaction on their transport 
The major question following the detected interactions was whether they had any 
consequences at the cellular level. This issue was first approached by examining the 
intracellular localizations of the interacting proteins in the absence of the Cln5 
protein. Interaction partners were transiently expressed in Cln5-deficient mouse 
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fibroblasts and detected by immunofluorescence staining. No difference was 
detected in the intracellular localization of the interacting NCL proteins (data not 
shown). Next, we analyzed their localization when co-expressed with CLN5 in 
HeLa cells. The intracellular localizations of the analyzed NCL proteins again 
remained unchanged, although CLN3 was often detected in the ER in addition to 
lysosomes. CLN5 was also partly retained in the ER with CLN3, possibly indicating 
a defect in their folding due to strong expression and the hydrophobicity of the 
transmembrane protein CLN3 (data not shown). 
We proceeded to analyze whether the disturbances in the intracellular trafficking of 
CLN5 would affect the trafficking of the interaction partners. To this end, we 
utilized transient overexpression of a C-terminally flag-tagged CLN5 construct, 
which is unable to leave the ER. Co-expressions were performed in HeLa cells. 
Interestingly, the wild type PPT1 was retained in the ER when co-expressed with 
CLN5-flag (III, Figure 2). To control the experiment, PPT1 was also co-expressed 
with a trafficking-deficient flag-CLN3 (data not shown) and CLN6, an ER-protein. 
When co-expressed with these proteins, PPT1 was able to leave the ER and was 
transported to lysosomes. The localization of the other interaction partners was 
normal with CLN5-flag, although again a fraction of CLN3 was retained in the ER 
(III, Figures 2 and 3). The total arrest in PPT1 transport was a strong indication of 
the importance of the interaction between CLN5 and PPT1, and we focused our 
further analyses on dissecting this observation. 
The ER-resident PPT1Fin mutant was co-expressed with the wild type CLN5 to 
investigate whether the transport defect was bilateral, i.e. whether trafficking-deficient 
PPT1Fin could retain the wild type CLN5 in the ER. However, during the co-
expression of wild type CLN5 and PPT1Fin, both polypeptides showed characteristic 
distribution in the majority of the experiments – wild type CLN5 was able to traffic to 
the lysosomes while PPT1Fin retained in the ER (III, Figure 4). Another CLN5 
polypeptide deficient in trafficking is the CLN5FinMajor protein, which carries the most 
common Finnish mutation (c.1175delAT, Y392X) (Savukoski et al. 1998). This 
mutant protein has been shown to localize in the ER and Golgi region but not in 
lysosomes (Isosomppi et al. 2002). The mutation results in an early stop codon 16 
amino acids before the C-terminus and consequent truncation of the polypeptide chain. 
When the wild type PPT1 was co-expressed with the mutated CLN5, the result was 
intriguing – PPT1 was observed to cluster into perinuclear vesicles, opposite to its 
normal, wide-spread vesicular distribution (III, Figure 4). The perinuclear vesicles 
where PPT1 was clustering were further analyzed in HeLa cells and in human 
neuroblastoma SH-SY5Y cells. They were proven to be mostly of late 
endosomal/lysosomal origin, as LAMP-1 colocalized with PPT1 (III, Figure 5). 
Sometimes PPT1 retention was stronger and it partially co-localized with the Golgi 
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marker GM-130 as well (Figure 9). More importantly, wild type PPT1 was able to 
facilitate the transport of the CLN5FinMajor polypeptides from the ER and Golgi region 
to the lysosomes, as CLN5FinMajor was also partly colocalizing with the PPT1/LAMP-1 
positive vesicles in addition to the localization in the ER and Golgi (Figure 9) (III, 
Figure 5). Furthermore, there seemed to be a correlation between the intensity of 
CLN5FinMajor expression and colocalization. When the CLN5FinMajor expression level 
was low, almost the entire signal appeared vesicular. When the expression was strong, 
most of the signal was seen in the ER. Without PPT1 co-expression, CLN5FinMajor was 
detected only in the ER and Golgi, as previously reported.  
 
Figure 9. Co-expression of CLN5FinMajor (A) and wild type PPT1 (B) in HeLa cells 
labeled with the Golgi marker GM130 (C). GM130 co-localizes partially with 
CLN5FinMajor (D) and PPT1 (E). In the overlay image (F), the colocalization 
of CLN5FinMajor and PPT1 is shown in yellow, and the colocalization of 
all three proteins in white. Scale bar 10 μm. 
Overlay
WT-PPT1 GM130
GM130 + CLN5-Fin GM130 + WT-PPT1
CLN5-Fin
A B C
D E F
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Consequently, our results implicated a role for PPT1 in CLN5 transport. The arrest 
of PPT1 transport in the ER when expressed with CLN5-flag possibly results from 
the strong interaction between the two proteins. However, its functionality cannot be 
assessed with these experiments. Regardless, as CLN5 is able to leave the ER 
without PPT1 most of the time, or the mutated PPT1 does not restrain its trafficking, 
it is the action of CLN5 on PPT1 that seems to be the important function in the ER. 
The relationship seems to be reversed in the Golgi region, where PPT1 facilitates 
CLN5. It is also possible that the clustering of PPT1 may result from dysfunctional 
CLN5. In any event, as both NCL proteins studied here are soluble and 
intravesicular, it is likely that the effect seen in their trafficking comes across via a 
third transmembrane protein functioning in the trans-Golgi region and participating 
in protein sorting events. The ability of PPT1 to enhance the lysosomal transport of 
the mutated CLN5 resembles the newly reported transport route for -
glucocerebrosidase. Interestingly, the transport of the mutant -glucocerebrosidase is 
enhanced by the overexpression of LIMP-2 (Reczek et al. 2007). However, the 
transmembrane protein, or the mechanism of how the information about the function 
of PPT1 and/or CLN5 affects the cytosolic face of the transport vesicle, remains 
undefined. A very interesting aspect here is the role of sortilin, another receptor for 
lysosomal transport and a protein participating in the trafficking of saposins. The 
storage material in INCL (and minor amounts in vLINCLFin as well), together with 
the reported delay in the transport of saposins A and D in Ppt1 deficient cells 
(Ahtiainen et al. 2006), offer a very good basis for studying the relationships 
between these three proteins in the future. 
5.3.3 The interaction between CLN5 and the F1-ATP synthase 
Because the interaction between CLN5 and PPT1 was strong, it was of interest to 
investigate whether CLN5 would also interact with the previously reported binding 
partner of PPT1, the F1-ATPase. Indeed, GST-CLN5 pull down analysis showed both 
F1-subunits,  and , to bind to CLN5 (III, Figure 6). To analyze if the two NCL 
proteins required each other in order to interact with the F1-subunits, the pull downs 
were performed from mouse tissue extract derived from the Ppt1- and Cln5-deficient 
mice. The interactions were positive in these conditions as well, implying that the 
proteins interact with the F1-ATPase independently. Disturbances in cellular and 
systemic lipid metabolism were observed in the Ppt1-deficient mice, and future studies 
will hopefully show whether the same is true in Cln5 deficiency. It will also be crucial 
to clarify the role of ectopic F1-ATPase in neuronal function, as discussed above. 
In summary, these results show that NCL proteins are connected at the molecular 
level, proposing a central role for CLN5 in the “common NCL-pathway” (Figure 
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10). Moreover, PPT1 was able to partially correct the transport of mutant CLN5. 
Finally, CLN5 was shown to interact with the F1-ATPase, thus linking PPT1 and 
CLN5 more tightly together functionally.  
 
 
Figure 10. The interactions between CLN5 and other NCL proteins described here. The 
interaction between CLN5 and PPT1, CLN8, and CLN6 occurs in the ER. 
The location of interaction between CLN5 and TPP1 or CLN3 is unknown. 
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6 CONCLUSIONS 
The genes behind INCL and vLINCLFin were characterized over a decade ago, and 
since then, a great amount of knowledge has been gained as far as understanding the 
molecular biology of these diseases. When this study was initiated, the function and 
three-dimensional structure of PPT1 had been described. It was known that PPT1 
was developmentally regulated in the human and mouse central nervous system, and 
the storage material accumulating in PPT1-deficient cells had been identified. PPT1 
had already been characterized extensively in non-neuronal cells, and studies 
examining PPT1 in neurons had been initiated. In addition, analyses on different 
disease mutations behind variable phenotypes had been initiated. However, the 
possible substrates of PPT1, or proteins functionally linked to PPT1, had not been 
identified in vivo. This work was initiated in order to characterize the neuronal 
properties and molecular interactions of PPT1, as well as to characterize the 
interactions of CLN5 with other NCL proteins. 
The major findings of this study were the identification of the F1-ATP synthase as an 
interaction partner of PPT1 and CLN5, as well as, on a more specific level, the 
neuron-specific alterations in the amounts of F1-subunits in Ppt1-deficient cells. 
Naturally, the results raise a cascade of further questions that need to be answered 
before the functional relevance of this interaction can be explained. However, initial 
evidence for a disturbance in lipid metabolism was detected in Ppt1-deficient cells of 
the central nervous system, together with alterations in the pattern of plasma lipid 
components. These findings are supported by previous results from gene expression 
studies and functional experiments performed on mouse neurons, describing 
alterations in cholesterol biosynthesis in young Ppt1-deficient neurons (Ahtiainen et al. 
2007). It will be of significant interest to analyze the parameters of lipid metabolism in 
Cln5-deficient neurons and plasma, and to determine whether similar aberrations are 
to be found in Cln5- and Ppt1-deficient mice. Further characterization of the defects 
linked to the disturbed lipid metabolism in NCL may also yield novel insights into the 
fundamental properties of neurons. It is likely that in the near future it will be possible 
to dissect whether the initial set of events in NCL pathogenesis are due to a 
dysfunction in neuronal development or whether this group of diseases is better 
characterized by neuronal degeneration, as originally assumed. 
Another interesting finding of this work was the rather strong interaction between 
PPT1 and CLN5, which affects the intracellular transport of the proteins. Given the 
specific involvement of the CNS in the pathogenesis of NCL disorders when 
compared to other lysosomal storage disorders, the intracellular membrane 
trafficking in neurons in general may turn out to be a salient point in these diseases. 
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NCL proteins should thus be kept in mind when dissecting the mechanisms of 
neuronal trafficking. Gene expression studies from Ppt1- and Cln5-deficient mouse 
cortices support the importance of the detected interaction between PPT1 and CLN5, 
since similar biological pathways were affected in both disease models (von Schantz 
et al. 2008). In this light, it will be interesting to in more detail also characterize the 
interactions between CLN5 and other NCL proteins described here. 
In this work, specific neuronal features of PPT1 were described. PPT1 was found to 
be differentially modified in neurons and fibroblasts, and to traffic differently from 
another lysosomal enzyme, AGA. These observations may provide clues for the 
altered intracellular localization of PPT1, although more work is needed to explain 
the eccentricities of neuronal trafficking per se before the underlying cellular events 
causing the death of neurons in PPT1 deficiency are clarified. The vital role of glial 
cells in the development and survival of neurons has only recently been recognized, 
and may prove to be crucial in NCLs as well as in other neurodegenerative diseases. 
This is supported by the link to lipid metabolism and altered particle size of apoE-
containing HDL lipoproteins in the Ppt1-deficient mouse sera, as the same 
apolipoprotein is linked to Alzheimer’s disease as well. It may turn out that the 
initial problem in NCL diseases is the cross-talk between neurons and glial cells 
rather than that between neurons. 
 In spite of both diseases being enriched in Finland, researchers in the US as well as 
in other parts of Europe have done much work to further our understanding of 
INCL, whereas Finns have up until recently been responsible for most of the 
vLINCLFin research. European collaboration funded by the EU, established to 
combine the powers of many small NCL research groups in Europe, was ongoing 
concurrently with this thesis work. This collaboration has been beneficial especially 
in advancing our understanding of the initial events in NCL disorders, and it 
initiated the systematic analyses of different NCL diseases (Cooper et al. 2006). 
These analyses continue, as high-throughput projects comparing different NCL 
diseases are on-going in an effort to elucidate their similarities and differences in 
terms of gene expression, metabolomics, and lipidomics (Jalanko et al. 2006). 
Collaborations between different fields of specialties are needed in the future when 
aiming to decipher the disease mechanisms behind NCL diseases. 
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